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SUMMARY 
Over the last decades, immunotherapy has become a mainstream approach in the treatment of 
cancer. Hopes within the scientific community were raised in particular by the 
groundbreaking success of blockading immune checkpoints, which tightly regulate the 
activity of immune effector cells by monoclonal antibodies (mAbs). Signal regulatory protein 
α (Sirp α) is a receptor mainly expressed on immune cells of the myeloid lineage such as 
macrophages or dendritic cells (DCs). It constitutes an immune checkpoint by binding its 
ligand CD47, which is ubiquitously expressed on all human cells. Interaction of Sirp α and 
CD47 inhibits signaling within the immune cell and leads to the “Don’t eat me” signal. In 
preclinical studies it has been shown that inhibition of the Sirp α-CD47 interaction by mAbs 
against CD47 leads to an increased phagocytosis of acute myeloid leukemia (AML) cell 
lines. Additional targeting of tumor cells by another tumor specific mAb even further 
increased the effect of tumor cell eradication.  
This work presents the creation and in vitro analysis of a newly-developed antibody 
derivative, which specifically targets AML cells and simultaneously inhibits the Sirp α-CD47 
interaction on CD16 expressing effector cells. We recombinantly linked either the naturally 
occurring Sirp α extracellular domain or an anti-CD47 single chain fragment variable (scFv) 
to a central anti-CD16 scFv and a C-terminal anti-CD33 scFv, yielding a molecule that we 
named a local inhibitory Checkpoint Antibody Derivative (liCAD). In order to express 
different liCAD molecules a new insect cell expression system was successfully established. 
We could obtain pure, monomeric proteins through a 3-step purification procedure and were 
able to detect binding of all individual binding domains.  
Subsequent in vitro data supported our hypothesis that the local blocking of CD47 on natural 
killer (NK) cells as well as macrophages induces tumor cell killing and phagocytosis, 
respectively. We could also show that the low affinity interaction of the extracellular domain 
of Sirp α within the liCAD with CD47 on cells leads to a preferential killing of CD47/CD33 
double positive cells compared to CD47 single positive cells. In addition, liCAD molecules 
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were tested on primary AML patient samples, where we could also show increased activation 
of NK cells compared to control constructs. 
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1. INTRODUCTION 
1.1. Antibody therapy of cancer 
1.1.1. History of antibody therapy 
The idea of a magic bullet, as phrased by Paul Ehrlich in the beginning of the 20th century, 
that could target specifically different antigens on cells was realized in 1975, when Kohler 
and Milstein developed a procedure to efficiently produce monoclonal antibodies (mAbs) 
through a technique called “hybridoma technology” (Kohler and Milstein, 1975). Strong 
hopes have been put into these very stable molecules, which seemed to be ideal regents for 
imaging and therapy. The initial excitement was soon replaced by disappointment, however, 
when serious problems were observed while using these proteins as therapeutics. The first 
attempts to use these molecules in therapy had the major drawback that they were of mouse 
origin and were therefore recognized as foreign when administered to patients leading to 
graft versus host disease. Furthermore, antibodies were not properly recognized by the 
patient’s immune system, resulting in severely restricted biological efficacy (Chames et al., 
2009).  
The advent of antibody engineering made it possible to create chimeric mAbs in which 
mouse variable domains, which bind the antigen on the target cell, are fused with human 
constant domains (Neuberger et al., 1985). These antibodies are 70% human and therefore 
exhibit considerably lower immunotoxicity. An even less immunogenic molecule could be 
generated by the development of a technology called “complementarity-determining region 
(CDR) grafting” (Jones et al., 1986). In these humanized antibodies, the CDRs (also referred 
to as hypervariable loops) of a human antibody are replaced by the hypervariable loops of a 
murine antibody, resulting in an 85-90% human antibody.  
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Since the approval of the first chimeric mAb in the late 1990, the rate of product approvals 
and sales of monoclonal antibody products has increased dramatically (as shown in Figure 1) 
and at this point in time, most of the approved mAbs used in clinical therapy are either 
chimeric, humanized or, more recently, fully human (Ecker et al., 2015).  
Figure 1 Annual approval of mAbs for therapy in the US and Europe. Overview of mAbs and derivatives 
that are either approved and on the market (green) or were approved and subsequently withdrawn from the 
market (blue). Figure taken from (Ecker et al., 2015). 
Impressive results were obtained in cancer therapy and the use of mAbs is now one of the 
most successful and important strategies for treating patients with blood cancer and even 
solid tumors. 
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1.1.2. Structure and function of mAbs 
In cancer immunotherapy the immunoglobulin G (IgG) format is by far the most promising 
of the five-existing immunoglobulin classes, due to its ability to bind to and activate Fc 
gamma receptors (FcγR), and thus induce an immune response.  
Monoclonal IgG antibodies are large proteins with a size of 150 kDa. They form homodimers 
with two identical heavy chains (of approximately 50 kDa each) and two identical light 
chains (of approximately 25 kDa each). From a structural point of view, the heavy chain is 
formed from four tandem immunoglobulin folds whereas the light chain is formed from two 
(depicted in Figure 2A).  
Figure 2 Structure of an IgG antibody. (A) Schematic representation of an IgG antibody with N-terminal 
variable domains followed by three or one constant domains in case of heavy and light chain, respectively. 
VH/VL and CH1/CL form the Fab fragment (fragment antigen binding) whereas CH2 and CH3 constitute the Fc 
fragment (fragment crystallizable). (B) X-ray crystallography revealed the Y-shaped three-dimensional 
structure of the IgG molecule. Each sphere represents an amino acid. Light chains are shown in blue and heavy 
chains are shown in grey. VH, variable domain of the heavy chain. VL, variable domain of the light chain. CH, 
constant domain of the heavy chain. Figure adapted from “Immunology: Understanding the immune system” 
(Elgert, 1998). 
Each fold consists of two anti-parallel β-sheets with an intra-molecular disulfide bond. 
Uniqueness is conferred upon the antibody by three loops, which are highly variable in 
length and sequence that connect the β-sheets within the N-terminal domains of each chain. 
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The six hypervariable loops or complementarity-determining regions (CDRs) form a unique 
surface that specifically recognizes and binds the antigen (Maynard and Georgiou, 2000). 
Figure 3 summarizes the natural effector functions of an antibody. In the simplest mode of 
action, the mAb binds and interferes with the activity and interaction of its binding partners, 
resulting in blockade of the receptor, receptor internalization or the induction of apoptosis. 
Whereas the Fab fragment of an antibody is responsible for antigen binding, the Fc part is 
responsible for not only its long half-life but also for its effector functions, including 
antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity 
(CDC) as well as antibody-dependent cellular phagocytosis (ADCP).  
Figure 3 Major functions of antibodies important in cancer immunotherapy. mAbs can induce antibody 
dependent cell-mediated cytotoxicity (ADCC) by inducing the release of cytotoxic granules in effector cells 
(e.g. NK cells) or antibody-dependent phagocytosis (ADCP). Other effector functions of mAbs include 
complement-dependent cytotoxicity (CDC), which starts with the binding of C1q to the antibody triggering the 
complement cascade, and the induction of apoptosis by activation of capsases. In addition, mAbs can block 
receptor/ligand interactions, preventing signaling cascade activation, or specifically deliver drugs into tumor 
cells by receptor internalization. Figure adapted from (Loureiro et al., 2015). 
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One of the most important effector functions for mAbs is the induction of ADCC as well as 
CDC as shown by the first mAb approved for cancer therapy, rituximab (Weiner, 2010). A 
more recent discovery is the application of mAbs that modulate immune cell function such as 
e.g. T cells by blocking so called immune checkpoints. 
1.2. Immune checkpoints 
When the immune system is responding to a pathogenic infection under normal physiological 
conditions, immune checkpoints prevent healthy cells and tissues from damage by 
maintaining self-tolerance (Pardoll, 2012).  
In case of T cells, for example, a reasonable activation depends first on the interaction of the 
T cell receptor (TCR) with the corresponding antigen and also on the regulation of the 
balance between co-stimulatory and co-inhibitory receptors on the immune cell. Recently, it 
has been discovered that the expression of immune checkpoint ligands can be dysregulated 
by tumor cells as a mechanism of escaping tumor immune surveillance. The importance of 
immune checkpoint inhibition was emphasized by the Science magazine, which awarded 
cancer immunotherapy the “breakthrough of the year 2013”, mainly due to the great success 
of mAbs against the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 
(PD-1) (Couzin-Frankel, 2013).  
Not only T cells are regulated by immune checkpoints, however. In the case of natural killer 
(NK) cells there also seems to be a balance between activating and inhibiting signals via 
corresponding receptors that induce potentially harmful effector functions. Indeed, increasing 
experimental evidence supports the idea that NK cell activation is under the control of 
different checkpoints. One of the most promising targets under close investigation are the 
killer cell immunoglobulin-like (KIR) receptors. KIRs bind to MHC class I on cells and 
transfer an inhibitory signal within NK cells. Blocking these receptors facilitates activation of 
NK cells and, potentially, destruction of tumor cells by the latter (Moretta et al., 2004). 
Macrophages as well as dendritic cells (DCs) are other possibly important immune cell 
populations that could be targeted by checkpoint inhibition. Macrophages express all classes 
of Fc receptors and a number of studies have shown that ADCP is a major mechanism during 
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antibody therapy. It has been recognized that the interaction of CD47 with the myeloid 
receptor signal regulatory protein alpha (Sirp α) serves as a myeloid-specific immune 
checkpoint that limits the response of macrophages to antibody therapies (Weiskopf and 
Weissman, 2015). Therefore, blocking of CD47 or Sirp α might be another powerful strategy 
to induce immunotherapy. 
1.2.1. Cancer immunotherapy market 
As mentioned above, two of the most prominent inhibitory receptors studied extensively in 
the last years are cytotoxic T-lymphocyte antigen 4 and programmed death-1, both of which 
are negative regulators of cytotoxic T cell activation. 
The first immune checkpoint mAb approved for malignant melanoma by the Food and Drug 
administration (FDA) in 2011 was an antibody against CTLA-4 called ipilimumab (trade 
name Yervoy; Bristol-Myers Squibb), which has subsequently been approved in more than 
40 countries. CTLA-4 counteracts the activity of the T cell co-stimulatory receptor CD28, 
most likely by outcompeting common binding partners CD80 (or B7.1) and CD86 (also 
known as B7.2) (Schwartz, 1992), and subsequently delivers an inhibitory signal to the T cell 
(Schneider et al., 2006). The second prominent checkpoint receptor is PD-1, which is mainly 
expressed on T cells in peripheral tissues during inflammatory response to infection and to 
prevent autoimmunity (Freeman et al., 2000; Ishida et al., 1992). It binds to PD-1 ligand 1 
(PD-L1) and PD-1 ligand 2 (PD-L2) and consequently inhibits kinases that are involved in T 
cell activation by the phosphatase SHP-2 (Freeman et al., 2000; Latchman et al., 2001). So 
far, two anti-PD-1 specific mAbs have been approved by the regulators for malignant 
melanoma. Nivolumab (trade name Opdivo; Bristol-Myers Squibb) was approved in July 
2014 in Japan and later by both the FDA and the European Medicines Agency (EMA). 
Prembrolizumab (trade name Keytruda; Merck & Co.) gained accelerated FDA approval for 
advanced and unresectable malignant melanoma in September 2014 (Webster, 2014). 
CTLA-4 and PD-1 represent two of the most prominent recently targeted checkpoints, but 
there are certainly various immune checkpoint receptors expressed on different effector cells, 
resulting in potentially different mechanisms of checkpoint inhibition and mobilization of the 
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immune system. Two further examples of inhibitory receptors on activated T cells are 
Lymphocyte activation gene 3 (Lag 3) and T cell membrane protein 3 (Tim3). The blocking 
of these receptors by mAbs is of great scientific interest and represents a novel strategy of 
unleashing the power of T cells to eradicate tumors (Grosso et al., 2009; Sakuishi et al., 
2010; Zhu et al., 2005). BMS-986016 (Bristol-Myers Squibb) for example is an anti-Lag 3 
antibody that is currently being tested in a phase I clinical trial. Another class of inhibitory 
receptors that are not only expressed on T cells but also on NK cells are KIRs. Their 
importance is well studied in NK cell activation as mentioned above and with BMS-986015 
(Lirilumab; Bristol-Myers Squibb) a first mAb against a KIR is currently enrolled in a phase 
II study (Pardoll, 2012; Webster, 2014).  
Market researchers predict that the immune checkpoint inhibitor market will experience 
enormous growth to approximately 7 billion US$ by 2020 across the seven major markets 
(US, France, Germany, Italy, Spain, UK and Japan) (Webster, 2014). 
1.2.2. Combination therapy 
Even though the advent of checkpoint inhibitors has revitalized the hope of successful 
antibody therapy to treat cancer, many clinical studies have revealed that many patients do 
not respond appropriately, if at all, to monospecific therapy (Chen et al., 2010). Considering 
the fact that cancer is often a multifactorial disease, in which tumors acquire mutations, it is 
not surprising that targeting a single tumor target does not appear to be sufficient to eliminate 
cancer cells (Spasevska et al., 2015).  
As outlined previously, the blockade of CTLA-4 and PD-1 has been proven to potently 
induce the T cell response to tumors when applied as single therapy. It has already been 
demonstrated in a pre-clinical B16 melanoma model that inhibition of both checkpoints in 
parallel leads to better killing of tumor cells because of the increased number of infiltrating T 
cells (Curran et al., 2010). Strikingly, clinical studies revealed that combining both mAbs led 
to an even higher overall response rate in advanced melanoma patients (Larkin et al., 2015; 
Tsai and Daud, 2015). 
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The immune system may be effectively stimulated by approaches other than the dual 
blockading of checkpoints. Advances in antibody engineering have facilitated the generation 
of novel antibody formats that can bind two or more different epitopes on tumor cells or 
immune cells or both. Different approaches to using these so called bispecific antibodies 
(bsAbs) are currently being used. Some antibodies are designed to target two different 
epitopes or antigens on tumor cells and thereby inhibiting two signaling pathways. In 
contrast, others are capable of binding immune cells and tumor cells, and thus link effector 
cells such as T cells, NK cell or macrophages with cancer cells, inducing the destruction of 
the latter. So far two main groups of bsAbs have been of great scientific interest: IgG-like 
bsAbs and small single chain fragment variable (scFv)-based bsAbs (Spasevska et al., 2015).  
The first successful Ig-like bsAbs to be generated and enter both clinical trials as well as 
clinics were TriomAbs® (Figure 4). TriomAbs® are mouse/rat chimeric antibodies, which are 
generated by somatic fusion of two hybridoma cell lines to form quadromas (Lindhofer et al., 
1995). In 2009 the EMA approved catumaxomab (trade name Removab; Fresenius Biotech), 
a trifunctional bsAb against Epcam and CD3, for the treatment of malignant ascites in 
patients with EpCAM positive carcinomas in cases where standard therapy is not available or 
no longer feasible (Chames and Baty, 2009). Catumaxomab surprisingly interacts with 
human activating Fc gamma receptors (FcγRI and FcγRIII) but not inhibiting Fc gamma 
receptors (FcγRIIB) and is thereby able to activate T cells as well as DCs, NK cells and 
macrophages (Zeidler et al., 2000; Zeidler et al., 1999). Nonetheless, side effects are 
frequently associated with catumaxomab and other strategies to produce less immunogenic 
molecules are therefore being widely studied.  
Progress in genetic engineering has made it possible to generate fully human molecules with 
even higher yields of functional bsAbs. Techniques such as the “knob-into-holes” approach, 
the common light chain approach, CrossmAb approach or the Dual-Variable-Domain Ig 
(DVD-Ig) approach pin hope on advanced and closer traditional IgG molecules for effective 
immunotherapy (Figure 4). One promising example is RO5520985 (Roche), a CrossmAb 
bsAb against Angiopoietin 2 (Ang2) and vascular endothelial growth factor (VEGF) that has 
shown in pre-clinical studies superior anti-tumor effects when compared to mAbs against 
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those factors alone (Kienast et al., 2013). This molecule is currently being tested in a phase I 
study for administration to patients with advanced solid tumors (Hidalgo et al., 2014). 
Figure 4 Different strategies for the generation of IgG-based bsAbs. Figure adapted from (Hess et al., 2014) 
The second class of bsAbs mentioned above is scFv-based bsAbs. Here one molecule, the 
BiTE, in particular caused excitement in the scientific community. A BiTE (bispecific T cell 
engager) consists of one scFv against CD3 and one scFv against a tumor antigen connected 
via a small flexible linker (Mack et al., 1995). They potently activate T cells by forming a 
lytic immunological synapse only upon binding of several molecules to the tumor antigen 
and CD3 expressed on T cells (Wolf et al., 2005).  
The FDA granted accelerated approval in December 2014 for blinatumomab (trade name 
Blincyto, Amgen) against acute B-cell lymphoblastic leukemia treatment, making it the first 
bsAb approved in the US (Sanford, 2015). Blinatumomab targets the surface antigen CD19, 
which is expressed on both healthy and malignant B cells, but it could be shown that the 
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elimination of normal CD19 positive B cells is tolerable. Active at very low concentrations, it 
has been shown to be highly effective in the treatment of patients with non-Hodgkin’s 
lymphoma (NHL) and in patients with relapsed or refractory B-precursor acute 
lymphoblastic leukemia (Bargou et al., 2008). This groundbreaking success raised hope that 
BiTEs could be used for the treatment of other hematological cancers, such as acute myeloid 
leukemia (AML), or even solid tumors. To date, Amgen has two more BiTEs against the 
epithelial cell adhesion molecule (EpCAM) and the carcinoembryonic antigen (CEA), 
respectively in phase 1 clinical trails (Spasevska et al., 2015).  
Although BiTEs are the only scFv-based bsAbs that have so far made it into the clinics, there 
are certainly more formats to be considered in the future, for example diabodies, triplebodies 
or tetravalent tandem diabodies, which exhibit a superior cytotoxicity and potency relative to 
diabodies (Holliger et al., 1993; Reusch et al., 2014; Schubert et al., 2011). 
Figure 5 Illustration of various scFv-based bsAbs. (A) Diabodies consisting of two scFvs connected via a 
flexible linker having either one specificity (bivalent) or two different specificities (bispecific), as in a BiTE 
molecule. (B) Triplebodies have three scFvs connected via flexible linkers and (C) tetrabodies have four scFvs 
connected.  
A new class of scFv-based bsAb was generated by the company Immunocore and is called 
Immune mobilising monoclonal TCRs Against Cancer (ImmTACs). ImmTACs target the 
major histocompatibility complex (MHC)-peptide complex and offer for the first time the 
possibility to target not only membrane antigens but also intracellular proteins of cancer cells 
(Oates and Jakobsen, 2013). It has to be pointed out that although small bsAbs are more 
effective in tissue penetration compared with larger IgG-based bsAbs, they exhibit shorter 
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half-lives and thus require continuous infusion. This suggest further improvements are 
required to increase their serum half-life (Chames et al., 2009).  
Surprisingly, no bsAb format that combines checkpoint inhibition together with tumor cell 
targeting within a single molecule has so far been brought into the clinic. There are, however, 
promising approaches under development. For example, there are attempts to redirect T cells 
to tumor cells with scFv-based modular systems fused to T cell stimulatory ligands (Arndt et 
al., 2014; Hornig et al., 2012). Furthermore, the Majeti group showed impressively in 2010 
that the targeting of cancer cells via one mAb against a tumor antigen and the additional 
blockading of an immune checkpoint using a second mAb has a synergistic effect in tumor 
cell elimination. Chao et al demonstrated in this study that in a NHL mouse model only 
administration of rituximab (an anti-CD20 mAb) together with an anti-CD47 mAb yielded in 
complete remission in five out of eight mice. In contrast, treatment of mice with either 
antibody alone led to death within 30 days. They concluded that the therapeutic effect of anti-
CD47 antibody in combination with rituximab is mediated primarily through macrophage 
phagocytosis and not through ADCC, CDC or apoptosis (Chao et al., 2010). The same group 
then developed an IgG-based bsAb co-targeting CD47 and CD20, which in pre-clinical NHL 
model experiments also showed reduced lymphoma burden and extended survival, thereby 
recapitulating the synergistic efficacy of anti-CD47 and anti-CD20 combination therapy 
(Piccione et al., 2015). The company NovImmune also realized the potential of blocking 
CD47 as a powerful strategy to increase immunotherapy. They developed an IgG-based bsAb 
against CD47 and CD19 for the treatment of B cell disease, which is currently in the pre-
clinical testing phase and anticipated to enter a clinical phase I trial in 2016 (NovImmune, 
2015).  
1.3. Leukocyte surface antigen CD47 
Leukocyte surface antigen CD47 was first purified from placenta and identified in the early 
1990s as a Rhesus factor related antigen on erythrocytes, but it was soon realized to be 
expressed on virtually all hematopoietic cells as well as other tissues. Furthermore, it was 
found to be the same as the integrin-associated protein (IAP), the ovarian tumor marker OA3 
and the protein Mer6 (Lindberg et al., 1994; Mawby et al., 1994).  
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CD47 is a 50 kDa cell surface glycoprotein of the immunoglobulin superfamily and has six 
potential glycosylation sites. Comparison of the human, mouse, rat and bovine CD47 protein 
shows a sequence identity of 60-70% in the amino acid sequence among these species. It has 
an extracellular N-terminal Ig-like V-type domain, a transmembrane-spanning domain with 
five transmembrane helices and a short alternatively spliced cytoplasmic tail. Four different 
splice isoforms, ranging from 4-36 amino acids, can be found in human as well as mice, each 
with different tissue expression patterns (Oldenborg, 2013). The main isoform that is 
expressed on all hematopoietic cells, as well as endothelial and epithelial cells is the 16 
amino acid form 2, while isoform 4 (36 amino acids) and 3 (23 amino acids) are expressed 
primarily in neurons, intestine and testes. Expression of the 4 amino acid form 1 is found in 
epithelial and endothelial cells (Reinhold et al., 1995). Even though tissue expression is well 
described, little is known regarding the functionality of the protein carrying different splice 
variants.  
Figure 6 CD47 binding partners. CD47 is a transmembrane glycoprotein with five transmembrane helices that 
is expressed ubiquitously throughout the body. It interacts in cis with integrins regulating cell movement and in 
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trans with thrombospondin, inhibiting angiogenesis, as well as with Sirp α, constituting a myeloid-specific 
immune checkpoint. Figure taken from (Slee et al., 2014). 
So far there are three main interaction partners known: integrins, thrombospondin-1 and 
signal regulatory (Sirp) proteins (depicted in Figure 6). In neutrophils CD47 was shown to 
act in cis on integrins, thereby regulating neutrophil migration across endothelial and 
epithelial cells during inflammatory response (Liu et al., 2001). Generation of CD47-
deficient mice further confirmed the importance of this protein in regulating neutrophil 
inflammatory responses, by showing an increased sensitivity to bacterial infection due to 
impaired neutrophil accumulation, which is caused by decreased neutrophil adhesion, 
phagocytosis and respiratory burst potential (Lindberg et al., 1996).  
The second interaction partner known is thrombospondin-1 (TSP-1). It belongs to the 
thrombospondin superfamily, a conserved family of extra cellular, oligomeric, multidomain, 
calcein-binding glycoproteins. They have many complex tissue-specific roles, including 
activities in wound healing and angiogenesis, vessel wall biology, connective tissue 
organization, and synaptogenesis (Adams, 2001). In platelets, TSP-1 activates the platelet 
integrin and induces platelet spreading as well as aggregation, and increased focal adhesion 
kinase (FAK) tyrosine phosphorylation, all of which are dependent on the CD47-integrin 
interaction (Chung et al., 1997).  
The third interaction partner mentioned here are the Sirp proteins. There are three Sirp 
proteins (α,β,γ) and they have similar extracellular regions but differ in their signaling 
potential. Sirp α has two immunoreceptor tyrosine-based inhibitory motifs (ITIMs), whose 
function will be explained in more detail in the following chapter. Sirp β has a very short 
cytoplasmic tail with no signaling motifs but its transmembrane region contains a positively-
charged lysine residue, which can bind the adaptor protein DNAX activation protein 12 
(DAP12/KARAP), which has an immunoreceptor-tyrosine-based-activating-motif (ITAM) 
(Tomasello et al., 2000). The third of the Sirp proteins, SIRP γ, has no recognizable signaling 
motif or ability to interact with cytoplasmic signaling molecules and is thus unlikely to 
generate intracellular signals (Barclay and Brown, 2006). CD47 was shown to be an 
interaction partner of Sirp α and Sirp γ (Brooke et al., 2004; Jiang et al., 1999) but not Sirp β 
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(Seiffert et al., 2001). The interaction between CD47 and Sirp α has been shown to be 
multifunctional in many body systems and will be discussed in the following sections.  
1.4. Signal regulatory protein α 
Sirp α was the first member of the Sirp family to be identified and is also known as protein 
tyrosine phosphatase, non-receptor type substrate 1 (PTPNS1), SHPS-1, CD172A and P84. It 
is primarily expressed on cells of myeloid origin, like macrophages, granulocytes or DCs, but 
also neurons and down-regulates immune response through phospho-tyrosine signaling 
mechanisms (van Beek et al., 2005).  
The extracellular region consists of three immunoglobulin superfamily domains: a distal IgV-
like domain, which interacts with the IgV-like domain of CD47, and two membrane proximal 
IgC-like domains (Fujioka et al., 1996; Kharitonenkov et al., 1997). An alternatively spliced 
form, which has only a single IgV-like domain, has also been identified (Veillette et al., 
1998). The intracellular region of Sirp α is highly conserved between rats, mice and humans 
and contains two ITIMs as mentioned above. Upon phosphorylation of the tyrosine residues 
within this motif, the Scr homology 2 (SH2) domain containing protein-tyrosine 
phosphatases SHP-1 and SHP-2 can bind, leading to the deactivation of myosin 2a and the 
initiation of actin depolymerization within the immune cell (Slee et al., 2014). In addition, 
two tyrosine phosphorylated adaptor proteins, SRC-family-associated phosphoprotein 2 
(SCAP2) and FYN-binding protein (FYB) (Timms et al., 1999), and the adaptor protein 
growth-factor-receptor-bound protein 2 (GRB2) (Kharitonenkov et al., 1997) can bind the 
ITIMs, however their downstream signaling functions remain to be identified. The 
interaction between CD47 and Sirp α was suggested to function as a “marker of self” and is 
highly species specific, with sequence identity between mice and humans in this region 
differing by only 38% (Subramanian et al., 2006).  
Functional studies have shown that the binding of Sirp α leads to an inhibition of cell 
activity, resulting in, for example, reduced phagocytosis by macrophages (Yamao et al., 
2002). Furthermore it could be shown in mouse knock-out studies that red blood cells 
(RBCs) isolated from CD47 knock-out mice and transferred to wild-type mice were rapidly 
cleared from the blood by macrophages (Oldenborg et al., 2000). Consistent with this, mice 
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expressing a cytoplasmic functionally inactive mutant of Sirp α also had an increased 
clearance of RBC (Ishikawa-Sekigami et al., 2006), which suggests that the CD47-Sirp α 
interaction acts as a “Don’t eat me signal” in macrophages.  
As mentioned above, the amino-terminal domain of Sirp α interacts with the amino-terminal 
domain of CD47. The spanning distance is therefore four IgSF domains, which corresponds 
to a distance of 14 nm, and is approximately the same as the distance between the interacting 
molecules in an immunological synapse between T cells and antigen presenting cells. 
Figure 7 Structure of Sirp α IgV-like domain (blue) bound to CD47. (A) A schematic representation of the 
5-transmembrane helix C-terminal domain of CD47 is shown. The interaction with SIRP α is mediated 
predominantly by loops at the NH2-terminal ends of the two molecules. The NH2 terminii of CD47 and Sirp α 
are designated with an ‘N’. (B) The overall distance between opposing cells is estimated to be around 14 nm 
from analysis of the CD47-SIRP α domain 1 structure and the SIRP α domain 1–3 structure. This distance is 
similar to that found in immunological synapses. Figure adapted from (Barclay and Van den Berg, 2014). 
It is very likely that CD47 does not constantly bind Sirp α because large abundant membrane 
proteins need to be redistributed for short-range interactions (Barclay and Brown, 2006). In 
terms of binding affinity of CD47 to Sirp α there are certainly various factors that can 
influence binding, such as the protein density on the cell surface and glycosylation. The 
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question of whether the dynamic range of an in vitro assay can reflect the in vivo situation 
also needs to be addressed. It has been reported that CD47 binds to Sirp α with a higher 
affinity (dissociation constant KD ≈2 μM) than to Sirp γ (KD ≈ 23 μM) (Brooke et al., 2004). 
These binding affinities are typical for many proteins containing IgSF domains, such as 
CD80 and CD86 binding to CD28 and CTLA-4 (0.2-20 μM) (Collins et al., 2002). It is 
important to bear in mind, however, that these values were determined with recombinant 
proteins in solution and may not represent the actual situation in vivo.  
As outlined above, Sirp α is primarily expressed on phagocytes, such as macrophages, but 
also DCs. Upon ligation of Sirp α with CD47, macrophages transmit a “Don’t eat me” signal 
that protects healthy cells from phagocytosis. Therefore the physiological role of this 
immune checkpoint is the orderly elimination of aged or apoptotic cells. Indeed it has been 
shown that CD47 expression is diminished or redistributed in apoptotic cells (Gardai et al., 
2005). Erythrocytes also lose CD47 from their cell surface as they age, leading to impaired 
Sirp α signaling and clearance of the cells by splenic macrophages (Oldenborg, 2004). 
However, it has been realized that macrophages also play a crucial role in cancer and even an 
more important role in mAb therapy for cancer, since they express all classes of Fgγ 
receptors (in contrast to NK cells expressing primarily FcγRIIIa) (Nimmerjahn and Ravetch, 
2008) and are thus capable of killing tumor cells via ADCP. 
1.5. The “Don’t eat me” checkpoint in acute myeloid leukemia  
The role of CD47 in cancer was first identified through studies of hematopoietic stem cells 
(HSCs) and leukemia. The authors found that HSCs upregulate CD47 in order to avoid 
phagocytosis by macrophages when they leave their niche and enter the blood stream 
(Jaiswal et al., 2009). They further screened various mouse as well as human leukemia cell 
lines and patient samples and repeatedly found that CD47 was upregulated. They particularly 
focused on acute myeloid leukemia (AML) stem cells and showed that the upregulation of 
CD47 protected those cells from macrophage uptake (Majeti et al., 2009). To test whether 
blockade of the Sirp α-CD47 checkpoint has an effect on AML stem cell engraftment and 
progression, they used mAbs against CD47 and impressively showed that engraftment was 
severely disturbed and AML was therefore depleted in vivo. They consequently hypothesized 
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that blockade of the CD47-Sirp α interaction could not only increase phagocytosis of tumor 
cells, but also that antigens from phagocytosed tumor cells may be presented to T cells and 
thus activate the adaptive immune response (Figure 8). 
Figure 8 Mechanism of action of CD47 blocking mAbs in AML. AML cells display MHC class I molecules 
as well as the CD47 surface markers of ‘self’. Engagement of tumor cells CD47 (“don’t eat me” signal) with 
macrophages SIRP α causes activation and phosphorylation of SIRP α ITIM motifs and the recruitment of 
SHP-1 and SHP-2 phosphatases. This prevents myosin-IIA accumulation at the phagocytic synapse from 
inhibiting tumor cell phagocytosis. By blocking the CD47-SIRP α interaction with antibodies (or alternate 
strategies) an increase in tumor cell phagocytosis by APCs is observed. Phagocytosed tumor cells are 
subsequently processed and tumor-associated antigens are presented by these APCs on their MHC. Naive tumor 
reactive T cells can then interact with MHC on APCs and these tumor-specific T cells are further activated, 
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expand, and are able to cause antigen-specific tumor cell cytotoxicity on remaining malignant cells. Figure 
adapted from (McCracken et al., 2015). 
Furthermore it has been shown that increased expression of CD47 on human AML is 
associated with poor clinical outcome, which makes it an interesting target in AML therapy. 
Acute myeloid leukemia is the most common myeloid disorder in adults and was 50 years 
ago incurable. Nowadays, AML is cured in 35-40% of patients who are 60 years old or 
younger, but only in 5-15% of patients who are older than 60 years old (Estey and Döhner, 
2006). The chances for a cure decrease drastically with increasing age, especially since older 
patients are often ineligible for intensive chemotherapy due to unacceptable side effects, 
which reduces the median survival to 5 to 10 months (Dohner et al., 2015). 
Prognostic factors can be subdivided into patient-related factors (like increasing age, 
coexisting conditions and poor performance status) and disease-related factors (e.g. white-
cell count, prior myelodysplastic syndrome or cytotoxic therapy for another disorder and 
leukemic cell genetic changes). Patient-associated factors commonly predict treatment-
assigned early death, whereas disease-associated factors predict resistance to current standard 
therapy (Dohner et al., 2015). Additionally, the identification of molecular markers (NPM1 
and CEBPA mutations and FLT3 internal tandem mutations) (Estey and Döhner, 2006) as 
well as the use of multiparameter flow cytometry to identify aberrant cell phenotypes are 
being used as predictive markers to assess therapy outcome (Grimwade and Freeman, 2014). 
The enormous heterogeneity of the disease, which makes it tremendously difficult to treat, 
has been realized over the last 15 years. AML is characterized by the clonal expansion of 
myeloid blasts in the peripheral blood, bone marrow or other tissues (O'Donnell et al., 2012) 
with the presence of both a founding clone and at least one subclone (The Cancer Genome 
Atlas Research, 2013). Due to the high incidence of relapse in AML there is the growing 
opinion that remaining malignant cells have stem cell-like properties and these have therefore 
been termed leukemia stem cells (LSCs) or pre-leukemic hematopoietic stem cells (Corces-
Zimmerman et al., 2014). Data from clonal evolution studies showed that genes involved in 
epigenetic regulation (like DNMT3A, ASXL1, IDH1 and TET2) are often mutated in these 
LSCs and occur early in the progression of AML (Shlush et al., 2014). Aside from being 
INTRODUCTION 
 
 
21 
capable of multilineage differentiation, they can survive chemotherapy and expand during 
remission, leading to relapse of disease. Furthermore they may share properties with normal 
HSCs or progenitor cells, which makes them difficult to target with conventional cancer 
treatments (Goardon et al., 2011).  
1.6. Conventional AML therapy 
After an initial assessment of the patient’s prognostic factors the method of choice in the 
treatment of AML is still chemotherapy. If the patient is eligible for intensive induction 
chemotherapy treatment starts with continuous-infusions of cytarabine with an 
antharacycline. A complete response is obtained in 60-85% of adults younger than 60 years 
old but the response rates are lower in older patients (40-60%). The reason for this is that 
older patients more frequently have a higher mutation load and other clinically relevant 
coexisting conditions. Such patients are thus less likely to benefit from induction 
chemotherapy and are instead candidates for investigational therapy (Dohner et al., 2015). 
In the case of positive response to induction chemotherapy, consolidation therapy is added in 
the event tumor cells are remaining. There are several options available, which again depend 
on the individual patient’s status. The preferred procedure consists of two to four cycles of 
intermediate-dose cytarabine (Lowenberg, 2013), however autologous as well as allogeneic 
hematopoietic-cell transplantation (HCT) may also be reasonable options (Koreth et al., 
2009; Vellenga et al., 2011). The curative effect of allogeneic HCT in patients with AML is 
contributed by the immunologic graft-versus-leukemia (GVL) effect. In order to avoid major 
side effects, such as graft-versus-host disease (GVHD), a human leukocyte antigen (HLA)-
matched donor is preferred but this still does not exclude GVHD. To prevent GVHD 
excessive immunosuppression is needed, which in turn can lead to fatal infections and 
recurrence of leukemia (Pasquini et al., 2012). Indeed the major complication appearing in 
transplantation therapy is the relapse of AML. New approaches under investigation include 
post-transplantation maintenance therapy, specific mutation inhibitors as well as targeted 
therapy immunotoxins, such as gemtuzumab ozogamicin (Dohner et al., 2015).  
Recurrence of AML occurs in most patients within the first three years after diagnosis. The 
disease outcome is determined again by various patient-related and disease-related factors 
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that define the salvage regimen. The intention is again to achieve a complete remission so 
that the patient can subsequently undergo allogeneic hematopoietic-cell transplantation. 
Patients who are unable to receive intensive salvage therapy can only receive low-intensity 
therapy, supportive care or, if they wish, new investigational therapies (Thol et al., 2015).  
1.7. Antibody therapy for AML 
Novel therapies with higher efficacy and lower toxicity are strongly needed for the treatment 
of AML. The selection of an appropriate antigen target is essential for the development of a 
successful antibody drug. The observation that ablation of the surface antigen CD33 cells 
could restore normal hematopoiesis in vitro in some leukemias with clonal dominance 
limited to granulocytes/monocytes suggested the myeloid differentiation antigen expressed 
on leukemic blast from 85-90 % of patients could be a valid target (Bernstein, 2000). The 
first trial with a mAb in AML therapy was performed 20 years ago with a mouse mAb 
against CD33 (Scheinberg et al., 1991). Further improvements resulted in the generation of 
lintuzumab, a humanized IgG1 version of the mouse mAb (Caron et al., 1992). Unfortunately 
lintuzumab showed no benefit in a phase 3 trial in patients with relapsed AML (Feldman et 
al., 2005).  
The first CD33-directed therapy approved by the FDA was the immunoconjugate drug 
gemtuzumab ozogamicin (trade name Mylotarg; Pfizer), which was approved in the year 
2000 on the basis of data from a non-randomized, phase 2 trial of 142 patients with relapsed 
disease (Bross et al., 2001; Larson et al., 2002). Gemtuzumab ozogamicin was withdrawn 
from the market in 2010, however, due to concerns about toxicity and lack of efficacy in a 
randomized phase 3 S0106 trial (Petersdorf et al., 2009). It has been shown in various 
studies, however, that lower doses of the drug (3-6 mg/m2 instead of 9 mg/m2) as well as 
different administration strategies (either single dose or fractionated) are safe and also 
effective. Meta-analysis of these studies evaluated that the addition of gemtuzumab 
ozogamicin to induction therapy significantly reduced the risk of relapse and improved 
overall survival rate at 5 years, especially in patients with favorable cytogenetic 
characteristics but also in those with intermediate characteristics (Hills et al., 2014).  
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Gemtuzumab ozogamicin is a recombinant, humanized (CDR-grafted) anti-CD33 
monoclonal antibody of the IgG4 isotype (clone hP67.6) covalently attached to the cytotoxic 
antitumor antibiotic calicheamicin (N-acetyl-γ-calicheamicin) via a bifunctional linker. Upon 
binding of CD33 the drug is internalized and chalicheamicin is released by hydrolysis into 
the leukemic cell. Once released intracellularly, single- and double-stranded DNA breaks are 
induced, resulting in a strong cellular response with cell-cycle arrest and subsequent DNA 
repair or, if the amount of damage is overwhelming, apoptosis and cell death, predominantly 
via mitochondrial membrane permeabilization and caspase activation (Linenberger, 2005).  
Not only gemtuzumab ozogamicin has shown promising results in CD33-directed AML 
therapy, however, as other groups have also developed bsAbs against CD33. Just as the 
CD19/CD3 BiTE blinatumomab has been shown to be very effective in lymphoblastic 
leukemias, a CD33/CD3 BiTE exhibited T cell recruitment and effective AML blast lysis in 
vitro as well as inhibition of tumor growth in preclinical in vivo models (Aigner et al., 2013; 
Arndt et al., 2013). Krupka et al evaluated the effect of AMG 330, a CD33/CD3 BiTE on 
primary AML patient material. They screened more than 600 patient samples for CD33 
expression on HSCs, LSCs as well as blasts, and showed that kinetics of T cell-mediated 
target cell killing were correlated with expression levels. Since LSCs have higher levels of 
CD33 expression than HSCs they suggested that AMG 330 will preferentially kill LSCs. 
Furthermore, the CD33 negative fraction of HSCs will be spared from AMG 330-mediated T 
cell killing and allow for restoration of normal hematopoiesis (Krupka et al., 2014).  
Another bsAb targeting CD16 and CD33 showed enhanced ADCC in vitro against AML cell 
lines as well as primary patient samples (Singer et al., 2010). Interestingly, a trispecific scFv 
triplebody (sctb) with the ability to dually target two different antigens (CD123 and CD33) 
on AML cell lines showed an even more increased efficacy compared with the bispecific 
format (Kugler et al., 2010). Since the surface antigen expression of CD123 was shown to be 
increased on the LSC compartment but not the HSCs (Jordan et al., 2000), CAR T cells 
against CD123 have also been generated as an effective treatment for AML therapy 
(Mardiros et al., 2013). The preclinical data from a CD123 mAb (clone 7G3) showed 
efficacy in AML therapy, however, as part of consolidation therapy, as 7G3 was much less 
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effective when given to mice 28 days after transplantation, when the leukemia burden was 
higher (Jin et al., 2009).  
As outlined previously CD47 was also reported to be a possible tumor target in AML. It has 
been shown that there is higher expression of CD47 in the LSC compartment than in normal 
HSC, and that increased expression of CD47 is a poor prognostic factor in patients with 
AML (Majeti et al., 2009). Many other surface markers have so far also been tested in 
preclinical experiments as well as clinical trials, such as TIM-3, WT1, CD96, CD44, CD52, 
VEGF or KIR, however the challenge will be to identify the best combinations for future 
AML therapy (Gasiorowski et al., 2014). 
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2. AIM OF THE THESIS 
Acute myeloid leukemia is a severe hematologic malignancy in which the prognosis remains 
poor despite advances in its treatment during the last three decades. Most patients, especially 
those of increased age, will relapse and approximately 60% of patients will eventually 
succumb to their disease. Novel therapies with increased efficacy and decreased toxicity are 
thus desperately needed. Immunotherapy has been realized as a very potent tool in cancer 
treatment, with its unique possibility to specifically target tumor cells via expressed tumor 
markers. The success of gemtuzumab ozogamicin has proven that firstly, CD33 is a valid 
target in AML and secondly, that antibody therapy is a useful supplement to induction 
therapy. A more recent discovery of considerable interest is that blockading immune 
checkpoints via mAbs utilizes the effector cells of the immune system to more efficiently kill 
tumor cells. In AML it was shown that the blockade of the CD47-Sirp α immune checkpoint 
by a mAb against CD47 increased the phagocytosis of tumor cells. In fact it could be 
demonstrated that the simultaneous blocking of the checkpoint and targeting of tumor cells 
via a mAb even increased tumor cell eradication.  
So far there is no antibody format available that combines immune checkpoint inhibition and 
tumor cell targeting. Therefore the aim of this thesis was to develop a novel antibody 
derivative that is able to specifically target AML cells via a high affinity anti-CD33 scFv, 
that is derived from gemtuzumab ozogamicin, and to locally block the CD47-Sirp α immune 
checkpoint via the naturally occurring extracellular Sirp α receptor domain. Use of the 
natural receptor domain should avoid systemic binding of the CD47 surface antigen that is 
expressed ubiquitously on human cells. Recruitment of CD16 expressing effector cells such 
as NK cells or macrophages is accomplished via another high affinity anti-CD16 scFv 
derived from the 3G8 mAb. The use of an scFv allows for stronger binding compared with 
the Fc stem of a mAb and more importantly, only binds to CD16 or FcγRIII, circumventing 
activation of all immune cells expressing various Fcγ receptors. Due to the rather weak 
interaction of the extracellular domain of Sirp α in the molecule to CD47 on the cells we call 
it a liCAD, which stands for local inhibitory checkpoint antibody derivative.  
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The main focus of this work was to first express and purify these molecules from human cells 
as well as insect cell culture, and second, to test their in vitro binding ability and biological 
activity on different AML cell lines. In collaboration with Prof. Marion Subklewe these 
molecules were then also tested for their biological activity on blast samples from AML 
patients.  
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Technical equipment 
Table 1 List of technical equipment used throughout this study 
Innova 44 Shaker New Brunswick Scientific 
T personal thermocycler Biometra 
Aekta Purifier 10, Explorer, Basic, FPLC GE Healthcare 
Cell culture laminar-flow  BDK Luft- und Reinraumtechnik GmbH 
HeraCell CO2 incubator  Thermo Scientific 
Multitron Cell incubator Infors HT 
Guava easy cyte HT Merck Millipore 
BD FACS Calibur BD Biosciences 
LSR II BD Biosciences 
Microplate reader Infinite M1000 Pro Tecan 
Inverted laboratory microscope Leica DM IL LED Leica 
Vi-CellTM XR cell viability analyzer Beckman Coulter 
Countess, automated cell counter Thermo Fischer Scientific 
Hemocytometer Neubauer improved Brand GmbH + Co KG 
Nanodrop ND-1000 Peqlab Biotechnologies GmbH 
Realtime system CFX96 BioRad 
Rotanta 460 RT centrifuge Hettich 
Tabletop centrifuges Eppendorf 
Sorval RC6+ centrifuge Thermo Scientific 
Novex® NuPAGE® SDS-PAGE Gel System Thermo Fischer Scientific 
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Agarose gel electrophoresis system BioRad 
Model 200 / 2.0 power supply  BioRad 
Mini-Trans Blot® electrophoretic transfer cell BioRad 
Minimate™ TFF Capsule Pall Life Sciences 
pH-meter 766 Knick 
Sartorius scale LE 22025 Sartorius AG 
Thermomixer comfort Eppendorf 
3.1.2. Software  
Table 2 List of software used to process data 
Graph Pad Prism GraphPad Software Inc. 
InCyte Software Merck Millipore 
Diva Software BD Biosciences 
Cell Quest Pro BD Biosciences 
 Adobe Illustrator Adobe 
3.1.3. Oligonucleotides 
Table 3 List of oligonucleotides used to clone and sequence expression constructs 
Name Sequence 
CD33scFv_KasI Fw AGATAGGCGCCGACATTCAGCTCACTCAG 
CD33scFv_STOP_EcoRV 
Rv 
AGATAGATATCTTAGCTAGACACTGTCACCAG 
CD16scFv_NotI Fw AGATAGCGGCCGCACAAGTGACACTGAAAGAGAG 
CD16scFv_XhoI Rv AGATACTCGAGGCTTGATTTCCAGCTTGGTG 
SirpIg BamHI Fw AGATGGATCCGAGGAGGAGCTGCAGGTGATTC 
SirpIg_GGGGS_ClaI Rv AGATAATCGATCCGCTCCCACCCCCCCCAGCAGAGGGTTT 
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GGCGCGCACAGAC 
GGGGS_ClaI Rv_SirpIg 
Fw (overlap) 
GGGGGGGGTGGGAGCGGATCGATTATGGCGGAGGAGGA 
GCTGCAG 
 SirpIg (G4S)4_NotI Rv CTTGTGCGGCCGCACTGCCGCCACCACC 
GGGGS_ClaI Rv_SirpIg 
Fw (overlap)_no 2nd ATG 
GGGGGGGGTGGGAGCGGATCGATTGAGGAGGAGCTGCAG 
 
Epcam1.1_KasI Fw AGATAGGCGCCGATATTCAGATGACCCAGAGCCC 
Epcam1.1_STOP_EcoRV 
Rv 
GCGGAGATATCTTATGAGCTAACGGTCAGCAGGGTTC 
C15G mutation exCD47 Fw GTAGAATTCACGTTTGGTAATGACACTGTCG 
C15G mutation exCD47 Rv CGACAGTGTCATTACCAAACGTGAATTCTAC 
exCD47-Fctag_NdeI Fw AGACATATGTGGCCCCTGGTAGCGGCGCTG 
exCD47 FcTag_NotI Rv AGAGCGGCCGCCTAATGATGGTGATGATGGTGTTTACCC 
GGAGACAGGGAGAGGC 
exCD47_ BamHI Fw GCGCGGATCCCAGCTACTATTTAATAAAAC 
exCD47_NotI Rv ATATGCGGCCGCGTGAAACAACACGATATTTTAG 
CD33 FL_AgeI Fw ATAACCGGTATGCCGCTGCTGCTACTGC 
CD33 FL_EcoRI Rv  ATAGAATTCTCACTGGGTCCTGACCTCTG 
S2-1 Fw_sequencing  GAACAAGCTAAACAATCTGC 
S2-1 Rv_sequencing GTATTAAAACATGACAATAC 
CD33scFv Rv_sequencing CCTGATACCATAGTTATCGAGAG 
CD33 FL Rv_sequencing CCCAGCAGTCTGAACCGGCCCTG 
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3.1.4. Amino acid sequences 
Table 4 Protein sequences of scFvs and extracellular domains 
Name Sequence 
N-terminal Ig domain of 
Sirp α (Sirp Ig) 
EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFR 
GAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGN 
ITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPS 
  
Sirp α high affinity (Sirp 
Ig_CV1) 
EEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRG 
AGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNI 
TPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPS 
Extracellular Sirp  (Sirp ex) EEELQVIQPDKSVLVAAGETATLRCTATSLIPVGPIQWFR 
GAGPGRELIYNQKEGHFPRVTTVSDLTKRNNMDFSIRIGN 
ITPADAGTYYCVKFRKGSPDDVEFKSGAGTELSVRAKPSA 
PVVSGPAARATPQHTVSFTCESHGFSPRDITLKWFKNGNE 
LSDFQTNVDPVGESVSYSIHSTAKVVLTREDVHSQVICEV 
AHVTLQGDPLRGTANLSETIRVPPTLEVTQQPVRAENQVN 
VTCQVRKFYPQRLQLTWLENGNVSRTETASTVTENKDGTY 
NWMSWLLVNVSAHRDDVKLTCQVEHDGQPAVSKSHDLKV 
SAHPKEQGSNT 
  
CD16 scFv (VL) DTVLTQSPASLAVSLGQRATISCKASQSVDFDGDSFMNWYQ 
QKPGQPPKLLIYTTSNLESGIPARFSASGSGTDFTLNIHPVEEE 
DTATYYCQQSNEDPYTFGGGTKLEIK 
  
CD16 scFv (VH) QVTLKESGPGILQPSQTLSLTCSFSGFSLRTSGMGVGWIRQPS 
GKGLEWLAHIWWDDDKRYNPALKSRLTISKDTSSNQVFLKI 
ASVDTADTATYYCAQINPAWFAYWGQGTLVTVSA 
  
CD33 scFv (VL) DIQLTQSPSTLSASVGDRVTITCRASESLDNYGIRFLTWFQQK 
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PGKAPKLLMYAASNQGSGVPSRFSGSGSGTEFTLTISSLQPD 
DFATYYCQQTKEVPWSFGQGTKVEVK 
  
CD33 scFv (VH) EVQLVQSGAEVKKPGSSVKVSCKASGYTITDSNIHWVRQAP 
GQSLEWIGYIYPYNGGTDYNQKFKNRATLTVDNPTNTAYM 
ELSSLRSEDTAFYYCVNGNPWLAYWGQGTLVTVSS 
  
CD47 scFv (VL) DIVMTQSPLSLPVTPGEPASISCRSSQSLVHSNGKTYLHWYL 
QKPGQSPRLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVE 
ADDVGIYYCSQSTHVPYTFGQGTKLEIK 
  
  
CD47 scFv (VH) QVQLVQSGAEVKKPGASVQVSCKASGYTFTNHVIHWLRQA 
PGQGLEWMGYIYPYNDGTKYNEKFKDRVTMTSDTSISTAY 
MELSSLRSDDTAVYYCARGGYYTYDDWGQATLVTVSS 
3.1.5. Buffers 
Table 5 List of buffers used for biochemical and cell culture methods 
 Buffer composition  
10 x PBS (1 l) 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4 x 2 H2O, 2 g KH2PO4, pH 7.4 
  
1 x PBS-T (1 l) 100 ml 10 x PBS, 0.1% Tween-20 
  
10 x transfer buffer (1 l) 30.3 g tris base, 144 g glycine 
  
1 x transfer buffer (1 l) 100 ml 10 x transfer buffer, 20 % ethanol 
  
4 x Laemmli buffer  0.11 M Tris (pH 6.8), 16% (v/v), 4% (w/v) SDS, 5% (v/v) β-
mercaptoethanol, 0.05% (w/v) bromophenol blue 
  
1 x MES SDS running MES pH 7.2 50 mM, Tris base 50 mM, SDS 0.1%, EDTA 1 mM, pH 
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buffer (1 l) 7.3 
  
Coomassie stain 50% (v/v) ethanol, 7% (v/v) acetic acid, 0.2% (w/v), 
Coomassie Brilliant Blue R250 
  
20 x ECL solution 2 M tris base, pH 8.5 
  
1 x ECL staining solution 
(10 ml) 
10 ml 20 x ECL solution, 3 µl H2O2, 25 µl cumaric acid, 50 µl luminol 
  
FACS buffer 1 % BSA, 1 mM EDTA, in PBS 
3.1.6. Antibodies 
Table 6 List of FACS and western blot antibodies 
Description Reactivity Isotype Clone Company 
CD47-PE Human Mouse IgG1 kappa CC2C6 BioLegend 
CD56-APC Human Mouse IgG1 kappa AF12-7H3 BioLegend 
CD16-PE Human Mouse IgM VEP13 BioLegend 
CD16-Alexa 647 Human Mouse IgG1 kappa B73.1 BioLegend 
CD33-FITC Human Mouse IgG1 kappa HIM3-4 BD Pharmingen 
CD3-FITC Human Mouse IgG2 HIT3 BioLegend 
penta HIS-Alexa 488 HIS tag Mouse IgG1  Quiagen 
HIS-HRP HIS tag Mouse IgG2b GG11-6F4.3.2 Miltenyi Biotec 
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3.2. Molecular biology methods 
3.2.1. Molecular cloning 
For bacterial expression of scFvs and SirpIg domains, all used scFvs as well as extracellular 
SirpIg domains were ordered at Geneart and cloned into the pAK400 vector behind the pELB 
leader sequence using SfiI restriction sites. Therefore, 1 μg of vector and insert DNA were 
incubated with 10 U of restriction enzyme and 1 x corresponding reaction buffer (all Thermo 
Fischer Scientific) and filled up with MilliQ H2O. Reactions were incubated for 1 to 2 hours 
at appropriate temperatures (according to manufacturer’s instructions) and then analyzed on a 
1 % agarose gel. Relevant DNA bands were cut out and a gel clean up was performed using a 
Nucleospin gel and PCR purification kit (Macherey-Nagel) according to the protocol.  
For ligation reactions, vector and insert DNA were mixed in a ratio of 1:2 and incubated with 
1 μl T4 DNA ligase, 1 x T4 DNA ligase buffer (both Thermo Fischer Scientific) and MilliQ 
H2O to a volume of 10 μl for 10 minutes to 1 hour at room temperature. The total ligation 
mix was then used for transformation reactions. 
Transformation of plasmid DNA was performed using chemically competent E.coli XL1 
Blue cells (Stratagene). Briefly, 100 μl of bacterial cells were mixed with 10 μl of plasmid 
DNA and incubated for 30 minutes on ice. Cells were then heat shocked for 45 seconds at 42 
°C and put on ice for 2 minutes again. After addition of 100 μl LB medium, cells were 
incubated for 1 hour at 37 °C and plated on an LB agar plate supplemented with 
chloramphenicol (34 μg/ml). The next day, single colonies were picked and cultured in LB 
medium containing antibiotics over night at 37 °C / 200 rpm, and plasmid DNA was isolated 
using an isolation kit (NucleoSpin Plasmid Easy Pure, Macherey Nagel). All sequences were 
verified by sequencing at Eurofins MWG Operon. 
For expression of liCAD proteins in human FreeStyleTM 293-F cells (Thermo Fischer 
Scientific), genes were cloned into the pSecTag vector after an Ig kappa leader sequence and 
a 6 x histidin tag. The front building block of the liCAD was always inserted using SfiI 
restriction sites, the middle one using NotI / XhoI, and the last one using KasI / EcoRV 
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restriction sites. Restriction digest, ligation reactions and transformations were performed as 
described above. E. coli cells were plated on LB agar plates supplemented with ampicillin 
(100 μg/ml). 
For expression of liCAD proteins in Drosophila melanogaster Schneider S2 cells 
(ExpreS2ion Biotechnologies), a BIP secretion signal followed by a 6 x histidin tag was 
cloned into the pExpreS2-1 vector or pExpreS2-2 vector (both ExpreS2ion Biotechnologies) 
using EcoRI / BamHI. Afterwards the liCAD was introduced via BamHI / EcoRV restriction 
sites after PCR amplification. The front module was then exchanged using SfiI restriction 
sites. Again restriction digest, ligation reactions and transformations were performed as 
described above. E.coli cells were grown on LB agar plates containing zeocin (50 μg/ml) or 
kanamycin (100 μg/ml). 
3.2.2. Polymerase chain reaction (PCR) 
Some scFvs were amplified by PCR from plasmid DNA using Phusion Flash Master Mix 
(Finnzymes, Espoo, Finnland) using primers as shown in Table 3. A typical PCR reaction 
contained 10-100 ng template DNA and 10 μM of each primer in 20 μl of 1 x PCR mix. 
The following PCR program was used: 
Cycle Temperature Time 
1 98 °C 30 sec. 
2 98 °C 10 sec. 
3 50 – 72 °C (depending on melting temp. of used primer) 20 sec.  
4 72 °C 20 sec. / 1 kb 
 Repeat 2 - 4  30 x 
5 72 °C 120 sec. 
6 4 °C pause 
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3.2.3. Site-directed mutagenesis  
To introduce an additional SirpIg domain on the N-terminal site of the liCAD, site-directed 
mutagenesis PCR was performed using Phusion Flash Master Mix. Therefore, 200 ng of 
plasmid DNA were mixed with 2 μM of each primer and 3 % DMSO in 20 μl of 1 x PCR 
mix.  
The following PCR program was used: 
Cycle Temperature Time 
1 98 °C 30 sec. 
2 98 °C 10 sec. 
3 50 – 72 °C (depending on melting temp. of used primer) 20 sec.  
4 72 °C 30 sec. / 1 kb 
 Repeat 2 - 4  20 x 
5 72 °C 120 sec. 
6 4 °C pause 
 
After the PCR amplification, 1 μl of DpnI restriction enzyme (Thermo Fischer Scientific) 
was added to the reaction tube and incubated for 3 hours at 37 °C to digest maternal plasmid 
DNA. Afterwards, 10 μl of the sample were transformed into chemically competent XL-1 
E.coli cells as described before. Colonies were screened, and positive clones were verified by 
sequencing. 
 36 
3.3. Protein biochemistry methods 
3.3.1. Periplasmic protein expression in E.coli 
To overexpress a scFv or extracellular SirpIg domains, pAK400 plasmids containing the 
corresponding open reading frames (ORFs) were transformed into competent E.coli BL21 
(DE) cells (NEB). Transformations were carried out as mentioned above, and cells were 
plated on LB agar plates supplemented with chloramphenicol (34 μg/ml). Several colonies 
were inoculated in a 50 ml pre-culture and grown over night at 37 °C in a shaking incubator 
at 200 rpm. The following day, 3 l LB cultures were inoculated 1:100 with the pre-culture 
and grown at 37 °C to an OD600 of ~ 0.7. The E.coli culture was then cooled down on ice to 
18 °C and protein production was induced by addition of 0.5 mM IPTG. Expression was held 
over night at 18 °C in a shaking incubator at 200 rpm and cells were collected the next 
morning at 5000 rpm for 10 minutes using a SLC 6000 rotor (Sorvall). Cell pellets were put 
on ice and protein purification was performed immediately.  
3.3.2. Purification of polyhistidine-tagged periplasmic proteins 
Bacterial cell pellets were resuspended in 100 ml of cold periplasmic lysis buffer (100 mM 
Tris pH=8, 1 mM EDTA, 500 mM saccharose) and incubated on ice for 30 minutes. After 30 
minutes of centrifugation at 4000 rpm, the supernatant was transferred to SS-34 tubes 
(Sarstedt) and centrifuged again for 15 minutes at 15000 rpm using a SS-34 rotor (Thermo 
Scientific). The supernatant was transferred to a fresh tube and dialysed over night against a 
100 x volume of PBS. In order to perform affinity chromatography as a first purification step, 
Ni2+-NTA agarose beads (Quiagen) were added, followed by rotation over night at 4 °C.  
The subsequent day, beads were collected at 4000 rpm for 5 minutes and loaded into a Bio-
Spin® chromatography column (Bio Rad). Beads were rinsed 3 times with washing buffer 
(20 mM Tris-HCl pH=9, 300 mM NaCl, 10 mM imidazol) and rinsed 6 times with elution 
buffer (20 mM Tris-HCl pH=9, 300 mM NaCl, 200 mM imidazol). All wash and elution 
steps were collected in eppendorf tubes and samples were analyzed by discontinuous 
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polyacrylamide gel electrophoresis (SDS-PAGE). Fractions containing the protein of interest 
were pooled and, depending on the purity, either subsequent size exclusion chromatography 
on a S75 10/300 GL column (GE Helathcare) was performed or the protein was immediately 
concentrated (Amicon spin concentrators, Millipore), aliquoted and shock frozen in liquid 
nitrogen. 
3.3.3. Expression of liCADs in human FreeStyleTM 293-F cells 
For expression of liCAD proteins, pSecTag vectors containing the desired ORFs were 
transfected into human FreeStyleTM 293-F cells using TransIT®-LT1 transfection reagent 
(Mirus Bio LLC) according to the manufacturer’s protocol. In brief, cells were sown at a 
density of 0.5 x 106 / ml the day before transfection. For a 20 ml culture, 20 µg of plasmid 
were mixed with 40 µl of TransIT-LT1 transfection reagent as well as 2 ml of OptiMEM® 
reduced serum medium (Thermo Fischer Scientific) and incubated for 20 minutes at room 
temperature. Afterwards, the mixture was added to the cells dropwise, and cells were 
incubated at 37 °C, 5 % CO2 in a shaking incubator for 5 to 7 days. In order to avoid 
clumping of the cells, between 6 and 12 hours after transfection anti-clumping factor 
(Thermo Fischer Scientific) was added to the medium at a dilution of 1:750. Cells were 
centrifuged at 1200 rpm for 5 minutes using a Rotanta 460 RF centrifuge (Hettich) and the 
supernatant was collected. Supernatants were either stored at -20 °C or used immediately for 
subsequent protein purification.  
3.3.4. Purification of polyhistidine-tagged liCADs from FreeStyleTM 293-F cell 
supernatant 
All liCAD proteins were designed containing an N-terminal polyhistidine tag. Therefore, cell 
culture supernatants were incubated with Ni2+-NTA agarose beads rotating over night at 4 ºC 
and subsequently affinity chromatography was performed as described in 3.3.2. Fractions 
were analyzed by SDS-PAGE and those containing the protein of interest were pooled and 
dialyzed over night at 4 ºC into a low salt buffer (20 mM Tris-HCl pH=9, 50 mM NaCl) in 
order to perform anion-exchange chromatography on a MonoQ 5/50 GL column (GE 
Healthcare) the following day. To separate the protein of interest from impurities, a 4-step 
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gradient of buffer A (20 mM Tris-HCl pH=9, 50 mM NaCl) and buffer B (20 mM Tris-HCl 
pH=9, 1 M NaCl) was performed as shown in Table 7. Peak fractions were again analyzed by 
SDS-PAGE and, according to purity, overexpressed proteins were either immediately 
concentrated and shock frozen or fractions were pooled and subjected to size exclusion 
chromatography on a Superdex 200 10/300 GL column (GE Healthcare) in a gel filtration 
buffer (20 mM Tris-HCl pH=9, 300 mM NaCl). SDS-PAGE of peak fractions was performed 
to confirm purity of the protein of interest and the fractions containing the protein were 
pooled, concentrated, shock frozen and stored at – 80 ºC.  
Table 7 Protocol of 4-step gradient purification 
 Number of column volumes (CV) / % buffer A and B  
1. step 5 CV 100 % buffer A, 0 % buffer B 
2. step 1 CV 10 % buffer B 
3. step 20 CVs linear gradient 10 % to 30 % buffer B 
4. step 16 CVs 100 % buffer B 
3.3.5. Expression of liCAD proteins in Schneider 2 cells 
In order to overexpress liCADs in insect cells, pS2-1 or pS2-2 vectors expressing the 
corresponding proteins were transfected into Drosophila melanogaster Schneider 2 (S2) cells 
using Lipofectamin® 2000 (Thermo Fischer Scientific) according to the manufacturer’s 
protocol. Briefly, Lipofectamin® 2000 was mixed with OptiMEM® in a 1 : 1 ratio and 
incubated for 5 minutes at room temperature. In parallel, 500 ng plasmid DNA per 1 x 106 
cells / ml were mixed with OptiMEM® in a proportionate ratio and later mixed with the 
Lipofectamin® 2000 / OptiMEM® solution in a 1 : 9 DNA : Lipofectamin® 2000 ratio. 
After 20 minutes of incubation at room temperature, the transfection mixture was applied 
dropwise to the cells.  
For the generation of a stably expressing S2 cell line, transfected cells were selected using 
either 2 mg/ml zeocin (Thermo Fischer Scientific) or 4 mg/ml G418 (InvivoGen) for 26 days 
according to the manufacturer’s protocol. In brief, cells were sown at a density of 2 x 106 / ml 
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in 5 ml EX-CELL® 420 medium (Sigma Aldrich) lacking fetal bovine serum (FBS) (Thermo 
Fischer Scientific), transfected as mentioned above and incubated at 27 ºC in a T25 flask 
(Sarstedt). After 4 to 6 hours, 1 ml of FBS was added and 24 hours afterwards the medium 
was supplemented with the corresponding selection agent. Cells were monitored daily, 
splitted thus if required (mostly every other day) and kept at a volume of 6 ml. After 14 days 
of selection, the total cell suspension was transferred to a T75 flask (Sarstedt) and kept at a 
volume of 15 ml until day 26, when the cells were finally transferred into a 125ml Corning® 
flask (Corning®) in EX-CELL® 420 medium with 10 % FBS without selection agent 
incubating in a shaking incubator at 27 ºC / 95 rpm.  
For expression of the desired protein of interest, cells were counted and sown at a density of 
8 x 106 / ml in EX-CELL® 420 medium without FBS. Expression was held over 4 to 5 days 
at 27 ° C in a shaking incubator at 95 rpm. Cells were centrifuged at 3000 rpm for 5 minutes 
in a Rotanta 460 RF centrifuge (Hettich) and the supernatant was collected. Supernatants 
were either stored at - 20 ºC or used immediately for further purification of the overexpressed 
protein of interest.  
3.3.6. Purification of polyhistidine-tagged liCAD proteins from S2 cell 
supernantant 
Collected supernatants were centrifuged in a SS-34 tube for 5 minutes at 15000 rpm in a SS-
34 rotor to ensure a cell- or debris-free protein solution. Afterwards, buffer exchange into 20 
mM Tris-HCl pH 8, 300 mM NaCl buffer was performed using a Minimate™ TFF Capsule 
(Pall Life Sciences) with an Omega™ 30 K membrane. As a first purification step, affinity 
chromatography was again performed as described in 3.3.2. Due to a higher amount of 
drosophila cell impurities, a further anion-exchange purification followed by an optional size 
exclusion chromatography was performed as outlined in detail in 3.3.4.  
3.3.7. Discontinuous Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein samples were analyzed by discontinuous polyacrylamide gel electrophoresis (SDS-
PAGE) (Laemmli 1970) using the Novex® NuPAGE® SDS-PAGE Gel System (Life 
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Thermo Fischer Scientific). Protein samples were mixed with Laemmli buffer, denatured for 
5 minutes at 95 °C and then separated on a NuPAGE® 4 – 12 % Bis-Tris gel (Thermo 
Fischer Scientific). Gels were run at 200 V in 1 x MES SDS running buffer, stained 
afterwards with Coomassie staining solution and destained in water. Table 5 summarizes 
buffer composition of buffers.  
3.3.8. Western blot analysis 
Protein samples were first separated according to size by SDS-PAGE as mentioned above 
and then transferred to a PVDF blotting membrane (BioRad) using a Mini-Trans Blot® 
electrophoretic transfer cell (BioRad). Therefore, three layers of Whatman paper, followed 
by the PVDF membrane, the SDS-PAGE gel and another three layers of Whatman paper, all 
presoaked in 1 x transfer buffer, were assembled in the blotting machine and the transfer of 
proteins to the membrane was carried out at 100 V for 60 min. The membrane was incubated 
in PBS-T / 3 % milk powder + 1 : 10000 anti-HIS antibody (Quiagen) for 60 minutes at room 
temperature and afterwards washed 3 times for 20 minutes with PBS-T.  
For detection of the proteins, the membrane was incubated for 1 minute with 1 x ECL 
staining solution, pat dried with a paper towel and immediately put into an exposure cassette. 
Exposure was carried out with a light sensitive Hyperfilm™ ECL™ (GE Healthcare). The 
films were developed in a Kodak X-Omat M35 developing machine. Used buffer 
compositions are summarized in Table 5. 
3.3.9. Small angle x-ray scattering (SAXS) 
Small-angle X-ray scattering (SAXS) data were collected at EMBL/DESY Hamburg 
beamline PETRA-3 P12. Protein samples after size-exclusion chromatography and 
centrifugation were measured at different concentrations between 0.7 and 2.6 mg/ml. Before 
and after each sample, the corresponding buffer was measured and used for buffer correction. 
No sample showed signs of aggregation or radiation damage, and scattering data were 
processed and analysed using programs of the ATSAS package (Konarev et al., 2006). 
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3.4. Cell culture methods 
3.4.1. Cell lines and media 
All human and hamster cell lines were either bought at the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ) or Thermo Fischer Scientific. Drosophila 
melanogaster Schneider 2 (S2) cells were bought at ExpreS2ion Biotechnologies.  
MOLM-13 
MOLM-13 cells are human cells established from the peripheral blood of a 20-year old 
patient suffering from acute myeloid leukemia. They grow in suspension and were 
maintained in RPMI 1640 + GlutaMAX (Thermo Fischer Scientific), 20 % FBS at a density 
of 0.5 – 2 x 106 cells / ml. The day before an experiment, cells were split to 0.5 x 106 cells / 
ml into fresh medium. 
OCI-AML3 
OCI-AML3 cells were kindly provided by Prof. Marion Subklewe. OCI-AML3 cells are a 
human cell line established from the peripheral blood of a 57-year old patient suffering from 
acute myeloid leukemia. Cells grow in suspension and were maintained in RPMI 1640 + 
GlutaMAX, 10 % FBS at a density of 0.5 – 2 x 106 cells / ml. The day before an experiment 
cells were split to 0.5 x 106 cells / ml into fresh medium. 
Jurkat  
Jurkat cells are human cells established from the peripheral blood of a 14-year old patient 
with acute lymphoblastic leukemia (ALL). They grow in suspension and were maintained in 
RPMI 1640 + GlutaMAX, 10 % FBS at a density of 0.5 – 2 x 106 cells / ml. 
THP-1 
THP-1 cells were established from the peripheral blood of a 1-year old boy suffering from 
acute monocytic leukemia. Cells grow in suspension and were maintained in RPMI 1640 + 
GlutaMAX, 10 % FBS at a densitiy of 0.1 – 1 x 106 cells / ml. 
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FreeStyleTM 293-F HEK cells 
The FreeStyleTM 293-F cell line is derived from 293 HEK cells and is adapted to suspension 
cell culture in FreeStyleTM 293 expression medium (Thermo Fischer Scientific) without FBS. 
Cells were kept shaking at 125 rpm in 125 ml Erlenmeyer flasks (Corning) at a density of 0.5 
– 2 x 106 cells / ml. The day before transfection, cells were split to 0.5 x 106 cells / ml into 
fresh medium. 
Flp-INTM -293 cell line 
Flp-INTM-293 cells are 293 HEK cells with a stably integrated FRT site at a transcriptionally 
active genomic locus. Cells grow in adherent culture and were maintained in DMEM + 
GlutaMAX (Thermo Fischer Scientific), 10 % FBS, 50 µg / ml zeocin to a confluence of 80 
% - 90 %. 
CD33-Flp-INTM-293 cells 
CD33-Flp-INTM-293 cells were kindly provided by Monika Herrmann and are transfected 
with the eukaryotic expression vector pcDNATM / FRT containing full-length human CD33. 
Cells grow in adherent culture and were maintained in DMEM + GlutaMAX, 10 % FBS, 100 
µg / ml hygromycin B gold (InvivoGen) to a confluence of 80 % - 90 %. 
Flp-INTM -CHO cell line 
Flp-INTM-CHO cells are Chinese hamster ovary cells with a stably integrated FRT site at a 
transcriptionally active genomic locus. Cells grow in adherent culture and were kept in 
Ham’s F-12 medium (Biochrom), 10 % FBS, 100 µg / ml zeocin to a confluence of 80 % - 90 
%. 
CD33-Flp- INTM-CHO cells 
CD33-Flp-INTM-CHO cells were created by transfecting the eukaryotic expression vector 
pcDNATM / FRT containing full-length human CD33 into the parental Flp-INTM-CHO cell 
line.  Cells grow in adherent culture and were maintained in Ham’s F-12 medium, 10 % FBS, 
550 µg / ml hygromycin B gold to a confluence of 80 % - 90 %. 
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CD47-Flp- INTM-CHO cells 
CD47-Flp-INTM-CHO cells were transfected with the eukaryotic expression vector 
pcDNATM / FRT containing full-length human CD47. Cells grow in adherent culture and 
were maintained in Ham’s F-12 medium, 10 % FBS, 550 µg / ml hygromycin B gold to a 
confluence of 80 % - 90 %. 
CD16-CHO cells 
CD16-CHO cells were kindly provided by Claudia Roskopf. Cells stably express full-length 
human CD16, grow in adherent culture and were maintained in Ham’s F-12 medium, 10 % 
FBS, 400 µg / ml G418 to a confluence of 80 % - 90 %. 
Schneider 2 (S2) cells 
Schneider cells are derived from a primary culture of late stage Drosophila melanogaster 
embryos. They grow both in a semi-adherent monolayer as well as in suspension and were 
maintained shaking at 95 rpm in EX-CELL® 420 medium with L-glutamine , 10 % FBS with 
a density of 5 – 50 x 106 cells / ml.  
3.4.2. Maintenance of cells 
All human cell lines were maintained at 37 °C, 5 % CO2. Cells were checked every day and 
passaged 2 times a week. In order to passage suspension cells, they were first resuspended, 
then mixed with trypan blue stain (0.4 %) in a 1:1 ratio and subsequently counted using a 
Countess automated cell counter (Thermo Fischer Scientific). For passaging adherent cells, 
medium was aspirated, cells were carefully washed with PBS (Thermo Fischer Scientific) 
and incubated with 1 ml of 0.05 % trypsin-EDTA (1 x) (Thermo Fischer Scientific) for 2 – 3 
minutes at 37 °C in the incubator. Cells were loosened by carefully tipping the plate, and the 
enzymatic reaction was stopped by the addition of FBS containing media. Cells were counted 
as mentioned above and the respective amount was put back on the plate.  
Drosophila melanogaster Schneider 2 (S2) cells were maintained at 27 °C without CO2 
shaking at 95 rpm in an Innova 44 shaker (New Brunswick Scientific). A 1:3 dilution of cells 
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was counted using the Vi-CellTM XR cell viability analyzer (Beckman Coulter) and the 
respective amount of cells was put back into a 125 ml Erlenmeyer Corning® flasks to a total 
volume of 25 ml.  
3.4.3. siRNA mediated transient knock down of CD47 in FreeStyleTM 293-F HEK 
cells and transfection of control proteins 
20 ml of FreeStyleTM 293-F HEK cells were cultured in Erlenmeyer flasks at a density of 
0.5x106 cells / ml and transfected the next day with siRNAs as well as the expression plasmid 
as follows: First, 400 µl OptiMEM were mixed with 20 µl Lipofectamin RNAiMAX reagent 
(Thermo Fischer Scientific) and incubated for 5 minutes at room temperature. In the mean 
time, 400 µl OptiMEM were mixed with 10 nM ON-TARGET plus Human CD47 siRNA-
SMARTpool (Thermo Scientific), afterwards combined with the transfection reagent solution 
and dropped to the cells. Additionally, 2 ml OptiMEM, 20 µl expression plasmid and 40 µl 
TransIT were mixed, incubated for 20 minutes at room temperature and also dropped to the 
cells. After 4 days, the cells were centrifuged and incubated with anti-CD47 antibody as 
described below for flow cytometric analysis. Supernatant was collected and incubated over 
night with Ni2+-NTA agarose beads and the protein was purified as described in 3.3.4. 
3.4.4. Generation of CD47 and CD33 Flp-InTM CHO cell lines 
As mentioned above, CD47 and CD33 Flp-InTM CHO cells were generated by transfection of 
the eukaryotic expression vector pcDNATM / FRT containing human full-length CD47 or 
CD33, respectively. Cells were transfected with Lipofectamin 2000® according to the 
manufacturer’s protocol. Briefly, 1 x 105 cells were plated in a well of a 24-well plate in 500 
µl Ham’s F-12 Medium, 10 % FBS without antibiotics. The next day, cells were transfected 
with a DNA:Lipofectamin 2000® ratio of 1:2 at 80 % - 90 % confluence. Therefore, first 2 µl 
Lipofectamin 2000® were mixed with 48 µl OptiMEM and incubated for 5 minutes at room 
temperature. In the mean time 100 ng of pcDNATM / FRT vector were mixed with 900 ng 
pOG44 vector (1 : 9 ratio) and filled up to a total volume of 50 µl with OptiMEM. 
Afterwards Lipofectamin 2000® and DNA solutions were mixed, incubated for 20 minutes at 
room temperature and added dropwise to the cells. After 6 hours, medium was exchanged 
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and 48 hours after transfection positive clones were selected by adding 550 µg / ml 
hygromycin B gold to the medium. Selection medium was changed every other day and 
polyclonal cell lines were grown. After approximately 4 weeks, cells were passaged to a 10 
cm cell culture dish and subsequently analyzed for surface expression of CD47 or CD33, 
respectively. Positive clones were selected and aliquots were frozen in Ham’s F – 12 medium 
+ 10 % FBS + 10 % DMSO (Sigma) using a freezing container (Nalgene Mr. Frosty). After 3 
days, cells were transferred to a liquid nitrogen tank.  
3.4.5. Isolation of peripheral blood mononuclear cells (PBMCs) from whole 
human blood 
For PBMC isolation, 100 ml of donor blood were split up to 20 ml and filled up with PBS to 
50 ml. Further, 25 ml of blood-PBS mixture were carefully pipetted onto 12 ml of a Biocoll 
separating solution (Biochrom AG) and spun with 818 g for 30 min. at room temperature 
without acceleration and deceleration. Afterwards, the PBMCs were carefully removed using 
a disposable Pasteur pipette, washed twice with RPMI 1640 + GlutaMAX, 10 % FBS, 1 % 
HEPES buffer (Biocrom AG) and kept at 37 °C, 5 % CO2 for further experiments.  
3.4.6. Expansion of human NK cells from whole human blood  
PBMCs were isolated from 40 ml of human whole blood using a Biocoll gradient as 
described previously. PBMCs were washed twice in RPMI 1640 + GlutaMAX supplemented 
with 1 % HEPES buffer and 10 % FBS and furthermore plated at a cell density of 5 x 106 
cells / ml in RPMI 1640 + GlutaMAX supplemented with 5 % human serum (Thermo 
Fischer Scientific), 0.25 μg/ml IL-2 (Thermo Fischer Scientific) and 10 μg/ml OKT-3 
monoclonal anti-CD3 antibody (Biolegend). After 5 days cells were collected at 1200 rpm / 5 
minutes, washed with PBS and again plated in RPMI 1640 + GlutaMAX, 5 % human serum, 
0.5 % Pen/Strep and 0.25 μg/ml IL-2. The following 16 days the cells were split every other 
day to a cell density of 0.5 x 106 cells / ml and NK cell number as well as killing potential 
was assessed on day 1 (d1), d5, d9, d14, d21, repectively. In order to assess NK cell numbers, 
a CD3, CD16, CD56 surface marker staining was performed. On d21, cells were furthermore 
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pelletted at a cell density of 20 x 106 cells / ml and subsequently frozen down in human 
serum + 10 % DMSO using a freezing container. After 3 days, cells were then transferred to 
a liquid nitrogen tank.  
3.4.7. Cell staining and analysis of surface marker 
In general, all cells were counted as mentioned above and 1 x 105 cells were distributed to a 
v-bottom 96-well plate (Costar). Cells were centrifuged for 4 minutes at 1400 rpm, pellets 
were resuspended in 50 µl FACS buffer containing the antibody mixture of choice and 
incubated for 30 minutes on ice in the dark. For compensation, single stain controls of each 
antibody present in the mixture was performed. After the incubation, cells were washed with 
200 µl FACS buffer and finally taken up in fresh 200 µl FACS buffer before they were either 
analyzed on a Guava easyCyte 6HT (Merck, Millipore) or transferred to a polysterene round-
bottom tube (BD) and measured on a FACS CaliburTM (BD). 
3.4.8. Binding studies 
To check binding abilities of generated liCADs, 1 x 105 cells expressing the respective 
surface antigen were centrifuged as outlined in 3.4.7, taken up in 30 µl FACS buffer 
containing 15 µg / ml liCAD and incubated for 30 minutes on ice. After washing with 200 µl 
FACS buffer they were incubated with 50 µl FACS buffer containing 1:200 anti-HIS 
antibody and incubated again for 30 minutes on ice in the dark. Cells resuspended only in 
FACS buffer containing 1:200 anti-HIS antibody served as a background control. After 
washing again, cells were taken up in 200 µl FACS buffer and analyzed on a Guava easyCyte 
6HT. 
3.4.9. KD determination of liCADs 
To determine KD values of liCADs, 1 x 105 cells expressing the respective surface antigen 
were centrifuged, incubated with protein and stained with an anti-HIS antibody as outlined 
above, but cells were taken up in a dilution series from 0.01 µg / ml to 15 µg / ml liCAD. 
Again, cells resuspended only in FACS buffer containing 1:200 anti-HIS antibody served as 
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a background control and fluorescence intensity of the secondary anti-HIS antibody was 
measured on a Guava easyCyte 6HT. One drop of rainbow calibration particles (8 peaks, 3.0 
– 3.4 µm (BioLegend)) was diluted in 200 µl FACS buffer and served as a standard for 
fluorescence intensities. Obtained median fluorescence intensities of the different dilutions 
and particles were exported and converted to channel numbers using the respective rainbow 
calibration data sheet. Converted values were then further normalized and plotted as a dose-
response curve in Prism software (Graph Pad Software Inc.). The obtained dose-response 
curves were analyzed using a non-linear regression, one-site specific binding model, and KD 
values were determined. 
3.4.10. Cytotoxicity assay 
The cytotoxic bioactivity of liCADs was analyzed by determining the ability to induce cell 
lysis of target cells. Specific lysis was plotted against the logarithm of liCAD concentration 
using Prism software (Graph Pad Software Inc.). The obtained dose-response curves were 
analyzed using the integrated four parameter non-linear fit model. Calculated concentrations 
of half-maximal kill values (EC50) were used as indicators for bioactivity. 
For liCAD mediated killing of CD47+CD33+ MOLM-13 tumor cells, cryopreserved IL-2 
expanded NK cells were thawed in RPMI 1640 + GlutaMAX medium complemented with 5 
% human serum. MOLM-13 cells were split to a density of 0.5 x 106 cells / ml in RPMI 1640 
+ GlutaMAX supplemented with 20 % FBS 24 hours prior to the assay setup. The following 
day 1 x 106 MOLM-13 cells were labeled with 16.6 μg / ml calcein AM (Thermo Fischer 
Scientific) for 30 minutes at 37 °C and subsequently washed 3 times with RPMI 1640 + 
GlutaMAX supplemented with 10% FBS.  
To induce liCAD mediated killing of NK cells, IL-2 expanded NK cells and MOLM-13 cells 
were co-incubated at an effector-to-target ratio of 2:1 in RPMI 1640 + GlutaMAX + 10 % 
FBS in the presence of 10 nM to 0.1 pM liCAD (conc.(protein)) at 37 °C, 5 % CO2. 
Background was determined in samples containing only target cells (background MOLM), 
spontaneous lysis was determined in samples containing only target cells and effector cells 
(background NK) and maximal lysis was determined adding 50 µl of RPMI 1640 + 
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GlutaMAX + 10 % + Triton -   100 (Roth) to labeled target cells (max lysis). Values were 
determined in duplicates. After 4 hours, cells were spun down at 1200 rpm / 5 minutes, 100 
μl of medium were transferred to a 96-well black polystyrene plate (Nunc) and absorption at 
485 nm was measured using a TECAN plate reader.  
The specific lysis was calculated according to following mathematical equation:  
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 % = 100 ×  𝑐𝑜𝑛𝑐. 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑁𝑘max 𝑙𝑦𝑠𝑖𝑠 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑀𝑂𝐿𝑀  
3.4.11. Preferential lysis of CD47+ CD33+ target cells 
Since CD47 is a ubiquitously expressed surface marker on human cells, we wanted to 
demonstrate that the low affinity Sirp α domain within the liCAD indeed favors a preferential 
lysis of CD47+ CD33+ tumor target cells. In order to do so, a cytotoxicity assay was 
performed with mixed single positive and double positive cell populations. In more detail, 
1 x 106 Flp-INTM 293 HEK cells and CD33 Flp-INTM 293 HEK cells were calcein labeled as 
described above. Since HEK cells are human embryonic kidney cells, they express CD47 on 
their cell surface. Therefore, the unmanipulated Flp-INTM 293 HEK cells are single positive 
for CD47 and the transfected CD33 Flp-INTM 293 HEK cells are double positive for CD47 
and CD33. Both have consistent levels of CD47 since it is expressed naturally. Two reactions 
were set up side by side: One reaction containing calcein labeled CD47+ cells and unlabeled 
CD47+ CD33+ cells, and the second reaction containing unlabeld CD47+ cells and calcein 
labeled CD47+ CD33+ cells. In both reactions the ratio of single positive and double positive 
cells was 1:1. Target cells were co-incubated with PBMCs in an effector-to-target ratio of 2:1 
in RPMI 1640 + GlutaMAX + 10 % FBS in the presence of either maximal determined 
protein amount or evaluated half maximal kill values (conc. (protein)). Background was 
determined in samples containing only corresponding labeled and unlabeld HEK cells 
(background HEK), spontaneous lysis was determined in samples containing only 
corresponding labeled and unlabeld HEK cells and effector cells (background PBMC) and 
maximal lysis was determined by adding 50 µl of RPMI 1640 + GlutaMAX+ 10 % + Triton-
X 100 to corresponding labeled and unlabeld HEK cells (max lysis). Values were determined 
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in triplicates. Both reactions were incubated for 4 hours at 37 °C, 5 % CO2. Afterwards, cells 
were spun down at 1200 rpm for 5 minutes, 100 μl of medium were transferred to a 96-well 
black polystyrene plate (Nunc) and absorption at 485 nm was measured using a TECAN 
plate reader. 
The specific lysis was calculated again according to the following mathematical equation:  
𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑙𝑦𝑠𝑖𝑠 % =  100 ×  𝑐𝑜𝑛𝑐. 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑁𝑘max 𝑙𝑦𝑠𝑖𝑠 − 𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝐻𝐸𝐾  
Calculated values were illustrated in Prism software as a bar graph and p-values were 
determined using an unpaired t-test (p < 0.05).  
3.4.12. CD14-positive selection of monocytes  
In order to generate human M2 macrophages, monocytes were isolated from PBMCs using 
CD14 MicroBeads (Miltenyi Biotech) according to the manufacturer’s protocol. In short, 1 x 
107 PBMCs were pelleted and resuspended in 100 µl MACS buffer (Miltenyi Biotech). 20 µl 
of CD14 MicroBeads were mixed to the cell suspension and incubated for 15 minutes on ice. 
Afterwards, cells were washed with 2 ml of MACS buffer and centrifuged for 5 minutes at 
1200 rpm. After an MS-column (Miltenyi Biotech) was washed with 500 µl MACS buffer, 
the cell suspension was put onto the column in a magnetic separator (Miltenyi Biotech). 
CD14 cells are thereby bound to the magnet and will not flow through the column. Cells 
were washed 3 times with MACS buffer. Subsequently the column was removed from the 
magnetic separator and CD14+ monocytes were eluted into a fresh tube with 1 ml MACS 
buffer. For higher starting PBMC numbers, volumes of buffers used were adjusted 
accordingly. Finally, monocytes were washed with PBS, centrifuged, counted and either 
PKH67 stained or plated into 24-well plates at a density of 0.1 x 106 cells / well in X-Vivo 
medium (Lonza) containing 10 % autologous serum. 
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3.4.13. PKH67 staining of monocytes and THP-1 cells 
For staining of 2 x 107 monocytes or THP-1 cells, cells were resuspended in 1 ml DilC 
solution (Sigma Aldrich) in a glass tube. 2 µl PHK67 dye (Sigma Aldrich) were mixed with 1 
ml DilC solution and rapidly added to the cell suspension. Cells were incubated for 90 
seconds at room temperature and staining was stopped by addition of 2 ml autologous serum. 
After 1 minute, cells were washed with medium once and counted for further experiments.  
3.4.14. PKH26 staining of MOLM - 13 and THP-1 cells 
For staining of 2 x 107 MOLM-13 or THP-1 targets, cells were first carefully washed in 
serum free medium and further resuspended in 1 ml DilC solution. 4 µl PKH26 dye (Sigma 
Aldrich) were mixed with 1 ml DilC solution and rapidly added to the cell suspension. Cells 
were incubated for 5 minutes at room temperatur by periodically inverting the tube. 
Incubation was stopped by addition of 2 ml FBS and incubated for 1 minute. Afterwards 4 ml 
of medium was added, cells were spun down and transferred to a fresh tube. Cells were 
washed twice and finally counted for subsequent experiments.  
3.4.15. Generation of THP-1 macrophages 
THP-1 macrophages were generated by plating 0.1 x 106 THP-1 cells / well into 24-well 
plates and differentiating them for 2.5 days in RPMI 1640 + GlutaMAX medium 
complemented with 10 % FBS and 10 nM PMA (Sigma Aldrich). Afterwards, medium was 
exchanged and THP-1 macrophages were used for subsequent phagocytosis assays 
3.4.16. Generation of M2 macrophages 
M2 macrophages were generated by differentiating monocytes for 5 days in M-CSF 
containing medium. Therefore 0.1 x 106 monocytes were plated into 24-well plates in 400 µl 
X-Vivo medium + 10 % autologous medium + 1 % P/S containing 20 ng / ml M-CSF (R&D 
Systems) and cultured at 37 °C, 5 % CO2. After 3 days, medium was exchanged and on day 5 
macrophages were used for subsequent phagocytosis assays. 
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3.4.17. Phagocytosis assay 
PKH67 stained M2 macrophages or THP-1 macrophages were generated as described above 
and incubated with PKH26 stained MOLM-13 or THP-1 target cells, respectively, in an 
effector-to-target ratio of 2:1 in serum free X-Vivo medium. A 4-fold dilution series of 
liCADs was prepared and incubated at a concentration ranging from 100 µM to 0.1 µM with 
the cells for 2 hours at 37 °C, 5 % CO2. Macrophages with target cells only but no protein 
served as a background control. Polybead® Carboxylate Red Dye Microspheres 6 µm 
(Polysciences) incubated with macrophages instead of target cells were used as positive 
control. In order to exclude adhesion of target cells to the macrophages instead of 
engulfment, a control reaction with macrophages, target cells and protein was set up and kept 
for 2 hours at 4 °C. As an additional adhesion control, macrophages were pre-treated with 10 
µM cytochalasin D (Sigma Aldrich) and further incubated with target cells and protein. 
Treatment of macrophages with cytochalasin D inhibits actin polymerization and therefore 
prevents phagocytic activity. Assays were performed in triplicates or quadruplicates. 
After 2 hours incubation, cells were collected into 1 ml FACS tubes (BD) as follows: First 
supernatant was transferred, then wells were washed with 200 µl PBS. Macrophages were 
detached from plates by incubation with 100 µl 1x TrypLE Express Enzyme (Thermo Fischer 
Scientific) for 5 minutes at 37 °C, 5 % CO2. Reaction was stopped by addition of 100 µl FBS 
and cells were transferred to the corresponding FACS tubes after careful resuspension. Tubes 
were centrifuged for 5 minutes at 1200 rpm, the supernatant removed, pellets resuspended in 
100 µl FACS buffer and transferred to a v-bottom 96-well plate. Cells were centrifuged again 
and stained for CD16 as described in 3.4.7. Afterwards, cells were washed again, taken up in 
100 µl FACS buffer, transferred to fresh FACS tubes and analyzed on a LSR II flow 
cytometer (BD) using Diva Software (BD). 
Obtained data were exported into Excel and increase in phagocytosis was calculated by 
subtraction of the background control. Increase of phagocytosis was plotted against 
increasing concentration in a dose-response curve using Prism Software.  
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3.4.18. NK cell mediated cytotoxicity of ex vivo expanded AML cells 
Primary AML patient samples were ex vivo expanded on feeder cells in the AML long term 
culture system as described in (Krupka et al., 2014) for 7 days. Cytotoxicity assays were 
performed with healthy donor NK cells at effector-to-target cell ratios of  5:1 and 2:1. Cells 
were incubated on MS-5 feeder cells (Krupka et al., 2014)in a-MEM (PAN Biotech) ( 
supplemented with 12.5% fetal calf serum (FCS), 12.5% horse serum, 1% 
penicillin/streptomycin/glutamine recombinant human granulocyte-colony stimulating factor 
(rhG-CSF), rhu interleukin (IL)-3 and rhu thrombopoietin (TPO) (Peprotech, Hamburg, 
Germany) and 57.4 mM 2-mercaptoethanol (Sigma-Aldrich, Munich, Germany)) for 24 
hours with 50nM of liCAD protein or no protein as a control condition. Subsequently cells 
were harvested and stained for CD16, CD56 and CD33 and analysed by flow cytometry. 
Lysis of AML cells was assessed flow cytometrically and analysed using Graph Pad Prism 6.	
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4. RESULTS 
4.1. Cloning and expression of liCADs in FreeStyleTM 293-F cells 
The coding genes for the extracellular domains of Sirp α (Sirp ex), Sirp α N-terminal Ig 
domain (SirpIg) and high affinity Sirp α (SirpIg_CV1) as well as for the scFvs of anti-CD47 
(αCD47), anti-CD16 (αCD16) and anti-CD33 (αCD33) were PCR amplified and cloned into 
the eukaryotic expression vector pSecTag 2 Hygro B according to 3.2.1 and transfected into 
FreeStyleTM 293-F cells. Figure 9 illustrates a schematic representation of different liCADs 
used throughout this study.  
Figure 9 Construct design of liCADs. Checkpoint inhibition domains were cloned N-terminally, followed by a 
central anti-CD16 scFv serving as effector recruiting domain and the C-terminal anti-CD33 scFv tumor specific 
domain. In yellow the extracellular domain Sirp ex is shown, in orange and red constructs containing one or two 
extracellular SirpIg domains are shown, whereas in grey control constructs are illustrated. 
As N-terminal checkpoint inhibition elements either the extracellular domain Sirp ex 
consisting of one Ig-like V type domain followed by an Ig-like C1 type 1 domain and an Ig-
like C1 type 2 domain or the Ig-like V type domain SirpIg was used. In order to increase 
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avidity for CD47 a double SirpIg construct was generated, connecting two SirpIg domains 
with a five amino acid linker (GGGGS linker). As control constucts for CD47 blockade the 
published high affinity mutant SirpIg_CV1 was used as well as an anti-CD47 scFv, 
consisting of a variable heavy (VH) and variable light (VL) chain connected by one GGGGS 
linker. All liCADs contain a central anti-CD16 scFv, consisting of a VH chain connected by a 
(GGGGS)5-linker to the VL chain and performing effector cell recruitment. The C-terminal 
anti-CD33 scFv is composed of a VL chain connected to the VH chain by a (GGGGS)4-linker. 
Individual domains are connected by (GGGGS)4-linker. Due to the Igκ leader sequence 
within the expression vector, proteins were secreted into the cell culture medium. A N-
terminal hexa-Histidine tag (6xHIS) served as first capture step for protein purification. 
4.1.1. Expression of Sirp ex.αCD16.αCD33, SirpIg.αCD16.αCD33 and 
SirpIg.SirpIg.αCD16.αCD33 
Sirp ex.αCD16.αCD33 (95 kDa) as well as SirpIg.αCD16.αCD33 (72 kDa) and 
SirpIg.SirpIg.αCD16.αCD33 (85 kDa) were well expressed in FreeStyleTM 293-F cells as 
shown in Figure 10. Affinity chromatoraphy using Ni2+-NTA beads was used as a first 
capture step. Figure 10 illustrates the course of purification on a denaturizing SDS-PAGE 
gel. The protein was well bound to the Ni2+-NTA agarose beads and washed for three times 
to get rid of unspecifically bound protein. Negligible amounts of desired protein came off the 
beads during washing steps. However, intensiv effort to recover the complete protein amount 
did not improve the binding capacity of the protein to the beads. 
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Figure 10 Affinity chromatography of proteins expressed in FreeStyle 293-F cells. Ni2+-NTA purification 
of (A) Sirp ex.αCD16.αCD33, (B) SirpIg.αCD16.αCD33 and (C) SirpIg.SirpIg.αCD16.αCD33 shows already 
pure protein within elution fractions E1-E3. Marker (M), input of protein (IN), flow through (FT), wash 
fractions (W1-W4), and elution fractions (E1-E5). 
Elutions fractions 1-3 were pooled and a subsequent anionic exchange chromatography on a 
HiTrap Q column was performed. As shown exemplary for SirpIg.αCD16.αCD33 in Figure 
11B, the protein eluted in one main peak (I), followed by 2 shoulders (II and III). When 
analyzed on a denaturizing SDS-PAGE gel, all peak fractions contained the protein of 
interest. Analytical size exclusion chromatography on a Superdex 200 5/150 GL column 
revealed, that the main peak fraction I ran only in one peak, suggesting mainly monomer 
(Figure 11B), whereas fractions II and III contained a second peak, potentially indicating 
increasing amounts of aggregates (Figure 11C). Therefore, collecting the main peak after 
anionic exchange yielded in mainly monomer protein. Peak II and III were further pooled 
and monomer was separated from aggregate on a Superdex 200 10/300 GL.  
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Figure 11 Anionic exchange chromatography and size exclusion chromatography of 
SirpIg.αCD16.αCD33.  (A) Anionic exchange chromatography with a HiTrapQ column showed a main peak 
(I) with 2 shoulders (II and III) that also contained the protein of interest. (B) When subjected to analytical size 
exclusion chromatography on a Superdex 200 5/150 GL column a monomer could only be obtained in the main 
peak fraction I. (C) Within fraction II and III potential aggregation peaks were detected on size exclusion 
chromatography and monomer peaks could be separated again. Marker (M), input of protein (IN). 
The extracellular domain of Sirp α (37.5 kDa) as well as the N-terminal Ig-like V type 
domain only (14.2 kDa) was also expressed periplasmatically in E.coli BL21 cells. 
Denaturizing SDS-PAGE analysis of Sirp ex revealed a degradation band at the size of the 
N-terminal Ig-like V type domain only (Figure 12A), which suggested a higher instability of 
this protein compared to the SirpIg only.  
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Figure 12 Affinity chromatography of Sirp ex and SirpIg expressed periplasmatically in E.coli BL21 cells.    
(A) Sirp ex (37.5 kDa) elutes mainly in elution fractions E1 and E2, however a degradation band at around 15 
kDa is clearly visible. (B) SirpIg (14.2 kDa) elutes in elution fraction E1 and E2. Marker (M), pellet (P), input 
of protein (IN), flow through (FT), wash fractions (W1-W3), and elution fractions (E1-E6). 
As crystallization data have revealed that the N-terminal Ig V type domain of Sirp α is 
sufficient for binding to CD47 and separate expression of the extracellular Sirp α showed 
degradation bands when expressed in E. coli, we decided to carry out all subsequent studies 
with the SirpIg.αCD16.αCD33 protein only.  
4.1.2. Expression of SirpIg_CV1.αCD16.αCD33 and αCD47.αCD16.αCD33  
To purify control molecules that bind to CD47 (SirpIg_CV1.αCD16.αCD33, 72 kDa and 
αCD47.αCD16.αCD33, 85 kDa) the transfection and expression procedure was carried out 
in FreeStyleTM 293-F cells the same as described before. After incubation of the cell 
supernatant with Ni2+-NTA agarose beads, purification fractions were analyzed on a 
denaturizing SDS-PAGE gel. No protein could be detected in the input fraction as well as the 
wash and elution fractions (Figure 13A). However, flow cytometric analysis of transfected 
FreeStyleTM 293-F cells cells with fluorescently labeled anti-HIS antibody showed that 
protein was indeed well expressed but immediately bound to the FreeStyleTM 293-F cells due 
to high affinity for CD47 as illustrated in Figure 13B. 
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Figure 13 Expression of control constructs. (A) SDS-PAGE analysis of αCD47.αCD16.αCD33 did not show 
any eluted protein at a size of 85 kDa. Marker (M), pellet (P), input of protein (IN), flow through (FT), wash 
fractions (W1-W3) and elution fractions (E1-E4). (B) Flow cytometric analysis with anti-HIS antibody of 
FreeStyleTM 293-F cells 5 days after transfection revealed that protein was bound to the cells (red 
chromatogram). Untransfected cells incubated with anti-HIS antibody served as a background control and are 
represented in grey.  
4.2. siRNA mediated transient knock down of CD47 in FreeStyleTM 293-F cells 
In order to avoid immediate binding of control molecules, CD47 was transiently knocked 
down using an ON-TARGET plus siRNA SMARTpool directed against CD47. As depicted 
in Figure 14A a partial knock down of CD47 could be obtained as can be seen by the 
decrease in fluorescence intensity of the CD47-PE signal. Comparison of untransduced 
FreeStyleTM 293-F cells stained for CD47 (red chromatogram) as well as the isotype control 
(grey chromatogram) with the transduced FreeStyle 293-F cells (blue chromatogram) shows 
that a full knock down of CD47 could by far not be obtained, but still parallel knock down of 
CD47 and expression of control proteins lead to lower binding probability to the FreeStyleTM 
293-F cells. Figure 14B shows a denaturing SDS-PAGE analysis of a Ni2+-NTA purification 
of αCD47.αCD16.αCD33 without (left) and with (right) CD47 transient knock down. 
Elution fraction E1 and E2 contain protein only in case of the CD47 knocked down FreeStyle 
293-F cells (marked with a red star). In case of SirpIg_CV1.αCD16.αCD33 even more 
protein could be obtained from affinity chromatography as shown in Figure 14C. 
Furthermore, these findings were confirmed by western blot analysis against anti-HIS tag 
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(Figure 14D). As shown, again only the elution fractions of the CD47 knocked down 
FreeStyleTM 293-F cells contained protein.  
Figure 14 Transient CD47 knock down of FreeStyle 293-F cells. (A) Flow cytometry reveals a partial knock 
down of CD47 when analyzing untransfected (red line), Lipofectamin RNAiMAX transfection reagents only 
treated (light grey dashed line) and ON-TARGET PLUS human CD47 SMARTpool treated (blue line) cells 
with anti-CD47-PE. Untransduced cells stained with an anti-CD47 isotype control are illustrated in dark grey 
and represent CD47 negative cells. (B) SDS-PAGE analysis of αCD47.αCD16.αCD33. Marker (M), Pellett (P), 
input (IN), flow through (FT), wash fractions (W1, W2), elution fractions (E1, E2). (C) 
SirpIg_CV1.αCD16.αCD33 after affinity chromatography clearly shows protein in elution fractions E1 and E2 
(red star) only in the CD47 siRNA treated Freestyle 293-F cells compared to control cells. Marker (M), Pellett 
(P), input (IN), flow through (FT), wash fractions (W1, W2), elution fractions (E1, E2). (D) Western blot 
analysis against the HIS-tag further confirmed protein expression in E1 and E2 of CD47 knocked down cells. 
Pellett (P), input (IN), elution fractions (E1, E2). 
4.3. Cloning and expression of liCADs in Drosophila melanogaster Schneider 2 
cells 
Schneider’s embryonic Drosophila cell line 2 (S2) can be used for stable expression of a 
variety of recombinant proteins using vectors specifically engineered for protein expression 
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in Drosophila cells. As described for the eukaryotic expression system, also for the 
Drosophila expression system the coding genes for the extracellular Ig-like V type domain 
Sirp α (SirpIg) and high affinity Sirp α (SirpIg_CV1) as well as for the scFvs of anti-CD47 
(αCD47), anti-CD16 (αCD16) and anti-CD33 (αCD33) were PCR amplified and cloned into 
the Drosophila expression vector pS2-1 or pS2-2 and transfected into S2 cells. The signal 
sequence from the insect BiP gene was exploited to direct the recombinant protein through 
the secretory pathway of S2 cells into the culture medium. After buffer exchange using a 
Minimate Tangential Flow Filtration (TFF) system, soluble protein could easily be purified 
by Ni2+-NTA affinity chromatography as a first capture step. Figure 15A shows exemplary 
for SirpIg.αCD16.αCD33 the enrichment of protein of interest in elution fractions E1 to E3. 
Quite substantial amount of protein could also be seen in the wash fraction already, which is 
most likely due to the low affinity of the 6xHIS tag to Ni2+-NTA agarose beads. Therefore, 
only one washing step was performed. In addition to the protein of interest also some 
unspecific higher molecular weight proteins (above 200 kDa) were obtained, that could be 
removed by anionic exchange. To this end, elution fractions E1-E3 were pooled and 
subjected to a MonoQ 5/50 GL column using a 4-step gradient elution profile. As shown in 
Figure 15B, peak I contained only liCAD protein whereas unspecific S2 proteins could be 
separated and eluted in a later second peak (II). Elution fractions within the first peak were 
then further collected and subjected to size exclusion chromatography in order to separate 
aggregate from monomeric protein. Consequently, protein was loaded onto a Superdex 200 
increase 10/300 GL column and peak fractions were additionally analyzed on a denaturizing 
SDS-PAGE gel. As illustrated in Figure 15C, a smaller first peak eluted shortly before a 
main second peak, which represent a small aggregation peak and a main monomer peak of 
protein of interest. As a result, pure liCAD protein could be obtained in a 3-step purification 
procedure.  
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Figure 15 Protein purification of liCADs expressed in S2 cells. (A) Exemplary Ni2+-NTA chromatography 
shows a clear protein band at a size of 75 kDa in case of SirpIg.αCD16.αCD33. Marker (M), input (IN), flow 
through (FT), wash fraction (W1), elution fractions (E1-E3). (B) Anionic exchange chromatography using a 
MonoQ 5/50 GL column separates liCAD protein (peak I) from unspecific S2 cell proteins (peak II) Marker 
(M), input (IN). (C) Concluding size exclusion chromatography on a Superdex 200 increase 10/300 GL further 
separated aggregate (peak I) from monomeric protein (peak II). Marker (M), input (IN). 
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4.4. Small-angle X-ray scattering of SirpIg.αCD16.αCD33 and 
SirpIg.SirpIg.αCD16.αCD33  
The two main liCAD proteins, SirpIg.αCD16.αCD33 and SirpIg.SirpIg.αCD16.αCD33, 
were analysed by small angle X-ray scattering (SAXS), to verify that the protein in solution 
is indeed monodisperse and of multi-domain structure. For this purpose, three different 
concentrations (2.6 mg/ml, 1.5 mg/ml and 1 mg/ml) were measured in case of 
SirpIg.αCD16.αCD33 and two different concentrations (1.4 mg/ml and 0.7 mg/ml) were 
measured for SirpIg.SirpIg.αCD16.αCD33. 
As shown in Figure 16A, scatter blots of raw data already revealed a monomeric protein in 
solution. Further data transformation to a Kratky plot (Figure 16B) and a Guinier plot (Figure 
16C) strengthened the evidence of no present aggregates but properly folded protein in 
solution. Additionally the P(r) distribution (Figure 16D) clearly indicated a multi-domain 
protein being measured. 
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Figure 16 Data analysis of SAXS. (A) Scattering intensity plot of SirpIg.αCD16.αCD33 (red) and 
SirpIg.SirpIg.αCD16.αCD33 (orange). (B) Kratky plot as well as (C) Guinier transformation reveal properly 
folded and monomeric protein in solution. (D) P(r) distribution shows characteristic plots for multi-domain 
proteins. (E) Summary of I(0) and Rg values obtained from Guinier transformations and distance distributions.  
A low-resolution model of the structure could be obtained by calculating 10 models and 
averaging the best ones. The crystal structure of two scFv as well as of the N-terminal Ig-like 
V type domain of Sirp α could be fitted into it using Pymol, as shown for separate proteins in 
Figure 17A and in an overlay of both molecules in Figure 17B. 
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Figure 17 Structure modeling and fitting of liCADS. (A) Theroretical models of SirpIg.αCD16.αCD33 (red) 
and (B) SirpIg.SirpIg.αCD16.αCD33 (orange) could be calculated and crystal structures of scFvs as well as the 
N-terminal Ig-like V type domain of Sirp α were fitted to the liCAD density. (C) Overlay of both models. 
In summary, these data confirm that liCAD proteins are indeed monodisperse and of multi-
domain structure, which theoretically enables binding capability and further biological 
activity. 
4.5. Binding studies of liCAD proteins  
In order to test binding of liCAD proteins to cell surface antigens, we did binding studies 
using flow cytometry. Since CD47 is expressed on every human cell and thus also on human 
cell lines, liCADs could not be tested for binding to CD33 or CD16 due to a constant CD47 
binding. To overcome this problem, single domains of liCADs were purified and seperatly 
tested for binding to respective antigens.  
Figure 18 summerizes flow cytometric binding studies on THP-1, Jurkat and stably 
transfected CHO-CD16 cells used in this study. Proteins were incubated at a saturating 
concentration and binding to the target cell was further analyzed by incubation with a 
secondary anti-HIS tag antibody. Binding of Sirp α to CD47 is reported to be in the low μM 
range. Therefore, owing to the low interaction strength, binding of SirpIg could not be 
detected on Jurkat cells (A). Several other human cell lines (eg. Freestyle 293FTM cells, 
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THP-1 cells or MOLM-13 cells) were tested for binding studies but SirpIg binding could 
never be demonstrated (data not shown). For higher affinity CD47 binders, like the high 
affinity mutant SirpIg_CV1 and the anti-CD47 scFv, binding could be shown on THP-1 cells 
(B and C). Since THP-1 cells are of monocytic origin, they also express CD33 on their cell 
surface and thus, binding of the anti-CD33 scFv could be shown (D). Additionally, the 
immune cell-recruiting domain was checked for binding by using CHO cells stably 
transfected to express CD16. Here we could demonstrate that the anti-CD16 scFv is able to 
bind to its target antigen on a living cell. Dashed black lines represent target cells incubated 
with anti-HIS tag antibody only.  
Figure 18 Binding studies of separate liCAD domains on human cell lines. (A) Binding of the naturally 
occurring SirpIg to human CD47 on Jurkat cells could not be detected due to low interaction strength. (B) High 
affinity mutant SirpIg_CV1 binds to human THP-1 cells (C) as well as anti-CD47 scFv and (D) anti-CD33 
scFv. (E) Binding of anti-CD16 scFv could be detected using CD16 expressing CHO cells. Dashed black lines 
represent isotype controles. (F) Cell lines used for flow cytometric analysis. + indicates respective surface 
antigen expression. 
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4.6. Generation of CHO Flp-InTM cells stably expressing CD33 and CD47 
As CD47 is expressed ubiquitously on human cells, a cell system expressing only CD47 or 
CD33 had to be generated in order to get valid binding data on liCAD molecules. We chose 
Chinese hamster ovary (CHO) Flp-INTM cells that do not express human antigens and had 
FRT sites integrated at a transcriptionally active genomic locus. Consequently, upon 
transfection of an Flp-INTM expression vector, targeted integration and high level of 
expression of the protein of interest is ensured. In order to generate CD47 and CD33 
expressing CHO cell lines, full-length human CD47 as well as CD33 were cloned into 
pcDNATM/FRT expression vectors as described in 3.4.4. Stable clones were raised over 
several weeks and antigen expression was analyzed by flow cytometry. As shown in Figure 
19A untransfected parental CHO cells were checked for human CD47 (red chromatogram), 
CD33 (blue chromatogram) and CD16 (green chromatogram) cell surface expression. As 
expected, none of the antigens could be detected on CHO cells. Individual established lines 
were then also checked for CD47, CD33 and CD16 expression (data not shown) however, as 
expected, cell lines were only positive for stably transfected antigens. Figure 19B 
summarizes most important surface marker expression analysis.  
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Figure 19 Characterization of CHO cell lines. (A) CHO Flp-INTM cells were first analyzed for CD47 (red), 
CD33 (blue) and CD16 (green) expression. Grey chromatograms with black dashed lines always represent 
corresponding isotype controls. (B) CD47 expression was confirmed in CHO-CD47 cells (red), CD33 in CD33 
transfected CHO cells (blue) and CD16 in CHO-CD16 cell lines (green).  
Flow cytometry of generated cell lines confirmed that CD47 is only expressed in CHO-CD47 
cells but not on CHO-CD33 and CHO-CD16 cells. Further, CD33 expression was solely 
shown in CHO-CD33 cells and CHO-CD16 cells were checked positively only for CD16 
expression. All cell surface stainings were compared to an isotype control of the respective 
antibody, which is shown in grey chromatograms with black dashed lines. 
4.7. Binding studies of liCAD proteins on CHO cell lines 
To test binding of individual liCAD domains within the full molecule, saturation binding 
assays were performed on stably transfected CHO Flp-INTM cells that only express CD47, 
CD33 or CD16, respectively. Bound liCAD protein was quantified by flow cytometry after 
staining with an α-HIS tag antibody coupeled to an Alexa Fluor 488 dye.  
Using the CHO-CD47 cells, SirpIg binding (Figure 20A) to CD47 could be detected, 
however, to a weaker extend than SirpIg.SirpIg (Figure 20B), as can be seen by the shifts in 
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mean fluorescence intensity in the histogram. Control molecules were also tested for binding 
to CD47 and as shown in Figure 20C and D αCD47 scFv binds less strong than the high 
affinity mutant of SirpIg, SirpIg_CV1. Binding of αCD33 scFv to CHO-CD33 cells as well 
as αCD16 scFv to CHO-CD16 cells could also be detected via flow cytometry. Both had 
similar shifts in mean fluorescence intensity, indicating likewise affinities. The grey 
chromatograms with dashed black lines represent CHO cells incubated with α-HIS tag 
antibody only as a background control. None of the molecules showed binding to CHO only 
cells (data not shown). 
Figure 20 Binding of individual liCAD domains to target antigens. (A, B) SirpIg (red) shows weaker 
binding to CD47-CHO cells compared to SirpIg.SirpIg (orange). (C, D) SirpIg_CV1 binds to CD47 with a 
higher affinity than the αCD47 scFv, as can be seen by shifts in mean fluorescence intensity. (E) αCD33 scFv 
binds to CHO-CD33 cells with high affinity (F) as well as αCD16 scFv to CD16 on CHO cells. Grey 
chromatograms with dashed black lines represent CHO cells incubated with α-HIS tag antibody only as a 
background control. 
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4.7.1. KD determination of liCAD proteins on CHO cell lines 
As shown in Figure 20 all liCAD molecules were able to bind to CD47 on CD47-CHO cells 
and therefore, dissociation constants (KD) could be evaluated. Bound liCAD was quantified 
by flow cytometry after staining with an anti-HIS tag antibody labeled with Alexa-488. KD 
values were calculated by computational analysis with Graph Pad Prism 6. Curves were 
normalized and fitted to a nonlinear fit, one site specific binding model and normalized mean 
fluorescence intensities were plotted against various liCAD concentrations. All 
measurements were performed in technical duplicates and repeated three times. 
The binding affinity for Sirp α to CD47 is reported to be in the low µM range as previously 
discussed. The measured KD-value for SirpIg.αCD16. αCD33 is 588 nM ± 240 nM (Figure 
21A). Considering the huge deviations within measurements it is obvious that a low affinity 
interaction is measured in this case. Duplication of SirpIg dramatically increases binding 
affinities since a KD-value of 21 nM ± 3.8 nM was determined, as shown in Figure 21B. 
Therefore, SirpIg.SirpIg.αCD16.αCD33 binds around 30-times stronger compared to 
SirpIg.αCD16.αCD33 and almost as strong as the high affinity mutant. 
SirpIg_CV1.αCD16.αCD33 binds with a KD-value of 16.9 nM ± 3 nM (Figure 21C) the 
strongest to CD47, which was expected since it is reported to be a high affinity mutant of 
wild type SirpIg. The KD-value of the second control molecule, αCD47.αCD16.αCD33, is 
147 nM ± 38 nM (Figure 21D), which is more than 8-times weaker than the high affinity 
mutant and is compared to the wild type SirpIg and double SirpIg in between binding 
affinities.  
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Figure 21 KD determination of liCAD molecules for CD47 binding on CD47-CHO cells was determined 
by flow cytometry. (A) Dissociation constant of SirpIg binding to CD47 is 588 nM ± 240 nM. (B) 
SirpIg.SirpIg binds to CD47 with a KD of 21 nM ± 3.8 nM and showed much stronger binding when compared 
to single SirpIg. (C) High affinity mutant SirpIg_CV1 binds with the strongest affinity to CD47 (16.9 nM ± 3 
nM). (D) KD determination of αCD47 scFv reveals 147 nM ± 38 nM, showing the second lowest binding 
affinity to CD47 compared to the other CD47 binders. Error bars represent standard error of the mean (SEM) of 
triplicates. 
KD values were also determined for αCD16 scFv and αCD33 scFv by incubating a serial 
dilution of SirpIg.αCD16.αCD33 on CD16-CHO or CD33-CHO cells, respectively. The 
dissociation constant for αCD16 scFv is 19.8 nM ± 3.4 nM (Figure 22A). For the αCD33 
scFv a KD value of 9.8 nM ± 2.6 nM was determined as shown in Figure 22B. 
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Figure 22 KD determination of liCAD molecules for CD16 and CD33 binding. (A) Binding of 
SirpIg.αCD16.αCD33 revealed a KD value of 19.8 nM ± 3.4 nM for CD16 binding. (B) αCD33 scFv binds with 
an afininty of 9.8 nM ± 2.6 nM to CD33-CHO cells. Error bars represent standard error of the mean (SEM) of 
triplicates.  
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4.8. Biological functionality of liCAD proteins 
4.8.1. Cytotoxicity assay with in vitro IL-2 expanded NK cells 
The potential of liCAD molecules to induce cytotoxicity on MOLM-13 cells, which is an 
AML cell line highly expressing CD33, was first tested with in vitro expanded NK cells as 
effector cells. Target cells were calcein labeled and incubated with effector cells at an 
effector-to-target ratio of 2:1 for 4 hours. Supernatants were analyzed for fluorescence 
intensities at 480 nm using a TECAN plate reader. The percentage of specific lysis was 
calculated as described in 3.4.10, data were transformed to logarithms and fitted to a 
sigmoidal dose-response equation in Graph Pad Prism 6. Half maximal effective 
concentrations (EC50) were calculated as indicator for specific bioactivity. All experiments 
were performed in technical duplicates and were repeated three times. 
As illustrated in Figure 23, SirpIg.αCD16.αCD33 (red curve) has a calculated EC50 value of 
341 pM (95% CI = 146 pM - 794 pM), which is almost 10-times higher than 
SirpIg.SirpIg.αCD16.αCD33 (39 pM (95% CI = 6 pM - 244 pM, orange curve). Compared 
to the bispecific control αCD33.αCD16 (black curve), that has an EC50 value of 1 060 pM 
(95% CI = 558 pM - 2 300 pM), one can appreciate that indeed dual targeting leads to an 
increased cytotoxicity on MOLM-13 cells. Control molecule SirpIg_CV1.αCD16.αCD33 
(grey curve, filled circle) has a calculated EC50 value of 3.2 pM (95% CI = 2 pM - 16 pM) 
and the half maximal effective concentration for αCD47.αCD16.αCD33 (grey curve, clear 
circle) is 101 pM (95% CI = 60 pM - 203 pM). These findings correlate with determined 
binding affinities, since molecules having a higher affinity for CD47 induce killing at a lower 
concentration than weaker binder. The control molecule (αHER2.αCD16.αHER2) did not 
induce cytotoxicity of HER 2 negative target cells, which excludes unspecific activation of 
NK cells by CD16 binding only.  
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Figure 23 LiCAD dependent cytotoxicity assay on MOLM-13 cells. SirpIg.αCD16.αCD33 (red) and 
SirpIg.SirpIg.αCD16.αCD33 (orange) show lower half maximal effective concentrations compared to the 
αCD33.αCD16 bispecific control. This suggests an increased cytotoxic potential of liCAD molecules possibly 
due to dual targeting of MOLM-13 cells. EC50 values of control liCADs SirpIg_CV1.αCD16.αCD33 (dark 
grey) and αCD47.αCD16.αCD33 (light grey) correspond to determined binding affinities to CD47. Error bars 
represent standard error of the mean (SEM) of triplicates. αHER2.αCD16.αHER2 (control) did not induce 
cytotoxicity. 
4.8.2. Cytotoxicity assay with primary NK cells 
In order to rule out, that liCAD induced cytotoxicity observed in assays with IL-2 expanded 
NK cells was not only due to pre-stimulation and activation of NK cells, we wanted to test if 
liCAD molecules also show biological functionality in unstimulated, none IL-2 expanded 
primary NK cells. To do so, MACS sorted NK cells from healty donors were kindly provided 
by Prof. Marion Subklewe.  
Assays were carried out as descibed above. Due to different healty donor NK cell samples, 
killing capacity of effector cells varied, which effected percentage of specific lysis of tumor 
cells. Therefore, one representative out of three performed experiments is shown.  
Figure 24A illustrates killing curves of NK cells incubated with CD33 high expressing 
MOLM-13 tumor target cells. The EC50 value of SirpIg.αCD16.αCD33 (red curve) is 22 pM 
(95% CI = 11.8 pM - 416 pM). Again the EC50 value was drastically lowered by duplication 
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of SirpIg (orange curve), yielding in an EC50 of 1.5 pM (95% CI = 0.02 pM - 114 pM). 
SirpIg_CV1.αCD16.αCD33 (dark grey curve) shows in turn the strongest killing capacity 
with an EC50 value of 0.6 pM (95% CI = 0.05 - 6.4 pM) and the half maximal effective 
concentration of αCD47.αCD16.αCD33 (light grey curve) was determined as 10.2 pM (95% 
CI = 1.5 pM – 69 pM). Comparing all liCADs to the bispecific controls, it is obvious that 
addition of a second tumor targeting domain increases cytotoxic activity, as can be seen by 
EC50 values of αCD33.αCD16 with 71.6 pM (95% CI = 10.4 pM - 492 pM) or 4800 pM 
(95% CI = 87.7 pM - 261 pM) in case of SirpIg.αCD16 (both black). Generally, all liCAD 
molecules showed equal killing potential independent of NK cell origin. Only EC50 values 
shifted to an even lower pM range, which could be explained by higher CD16 expression 
levels on primary NK cells compared to IL-2 expanded NK cells (data not shown). The 
αHER2.αCD16.αHER2 specificity control did not show any cytotoxic potential, indicating 
no unspecific NK cell activation upon CD16 binding also in primary material. 
In order to validate biological functionality of liCAD molecules also for cells expressing 
lower levels of CD33 on their surface, we performed liCAD dependent cytotoxicity assays 
with OCI-AML3 cells that were kindly provided by Prof. Marion Subklewe. As shown in 
Figure 24B the EC50 value of SirpIg.αCD16.αCD33 (red curve) is 17.3 pM (95% CI = 21.2 
pM - 141 pM) and for SirpIg. SirpIg.αCD16.αCD33 (orange curve) is 4.3 pM (95% CI = 
0.38 pM - 47.7 pM). Again, dual targeting of CD47 and CD33 increases biological activity as 
is demonstrated by the EC50 value of the bispecific controls αCD33.αCD16 with 411 pM 
(95% CI = 118.2 pM - 1.4 nM) as well as SirpIg.αCD16 with an EC50 value of 16.3 nM (95% 
CI = 954.7 pM – 279.3 nM) (both black). CD47 control construct 
SirpIg_CV1.αCD16.αCD33 (dark grey curve) shows in turn the strongest killing capacity 
with an EC50 value of 0.3 pM (95% CI = 0.031 - 2.3 pM) and the EC50 value of the triplebody 
αCD47.αCD16.αCD33 (light grey curve) was determined as 9.7 pM (95% CI = 0.1 pM - 
902 pM). 
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Figure 24 LiCAD dependent cytotoxicity assay using primary NK cells. (A) Redirected lysis assay of 
MOLM-13 cells shows that dual targeting of tumor target cells increases cytotoxic potential drastically, which 
can be seen by the EC50 values of SirpIg.αCD16.αCD33 (red) with 22 pM and SirpIg.SirpIg. αCD16.αCD33 
(orange) with 1.5 pM when compared to bispecific control αCD33.αCD16 with 9631 pM and SirpIg.αCD16 
with 14940 pM (both black). CD47 control molecules are shown in grey. One representative experiment is 
shown out of three. (B) Using OCI-AML3 cells, which are CD33 low expressing target cells, same trends in 
specific lysis of tumor cells and similar EC50 values compared to MOLM-13 cells can be seen. Only bispecific 
control molecules αCD33.αCD16 and SirpIg.αCD16 (both black) show drastic decrease in their half maximal 
effective dose. One representative experiment is shown out of three. 
Comparing half maximal effective doses of molecules between CD33 high and CD33 low 
expressing tumor cells, merely minor differences can be seen. Most importantly, only EC50 
values of bispecific molecules shift to higher values, meaning lower biological activity, in 
case of CD33 low expressing OCI-AML3 cells but not liCADs targeting CD47 and CD33. It 
has been shown that OCI-AML3 and MOLM-13 cells have comparable amount of CD47 
molecules on their cell surface (unpublished data). Thus, this effect cannot be due to higher 
CD47 levels on OCI-AML3 cells that compensate for lower CD33 levels. This suggests that 
simultaneous binding of CD47 and CD16 on the NK cell in combination with tumor targeting 
via CD33, probably leads to a costimulatory or additive activating effect in the effector cells.  
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To further evaluate the potential of liCAD molecules to induce serial lysis of tumor cells by 
individual NK cells we performed an effector-to-target-cell (E:T) ratio titration as shown in 
Figure 25. MOLM-13 cells were mixed with NK cells at an E:T ratio of 2:1, 1:1, 0.5: and 
0:1. Assays were performed with half maximal effective dose of corresponding liCAD 
molecules the way described above. Assays were performed in technical triplicate and 
repeated 3 times. 
Figure 25 Effector-to-target-cell ratio titration does not indicate serial lysis of NK cells. E:T ratio titration 
of liCAD molecules reveals similar specific lysis of tumor cells at ratios of 2:1 and 1:1 but a drop by half at 
0.5:1. Error bars represent standard error of the mean (SEM) of triplicates. 
E:T ratio titrations of SirpIg.αCD16.αCD33 (red bars) and SirpIg.SirpIg.αCD16.αCD33 
show similar specific lysis values in case of the ratio of 2:1 and 1:1. However, at a ratio of 
0.5:1 the specific lysis of tumor cells drops to more than half. Since the control reaction 
without NK cells (E:T is 0:1) shows in both cases approximate specific lysis values, this 
suggests a non-specific tumor cell lysis for reactions at an E:T ratio of 0.5:1. Also for control 
liCADs SirpIg_CV1.αCD16.αCD33 (dark grey bar) and αCD47.αCD16.αCD33 (light grey 
bar) as well as bispecific controls αCD33.αCD16 (black bars) and SirpIg.αCD16 (black/grey 
sripped bar) similar results are obtained.  
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4.8.3. LiCAD dependent phagocytosis  
As outlined in the introduction, the Sirp α-CD47 interaction is known to constitute a “Don´t 
eat me singal” in macrophages, dendritic cells and neutrophils. The approach to interrupt this 
interaction using αCD47-mABs has been proven successful in several pre-clinical studies 
(Chao et al., 2010; Liu et al., 2015). In order to analyse the ability of liCADs to indeed 
increase phagocytic uptake in macrophages, a phagocytosis assay was established. We first 
set out to establish a cell line based macrophage assay using the THP-1 monocytic cell line in 
order to be able to work in an autologous setting. To do so, THP-1 target cells were 
incubated with THP-1 macrophages as explained in detail in material and methods. 
Subsequently we performed assays with primary monocytes differentiated to CD16 
expressing M2 macrophages. 
THP-1 cell and MOLM-13 cells were stained with PKH-26 and incubated with PKH-67 
stained THP-1 macrophages or M2 macrophages, respectively, for 2 hours in serum free 
conditions at an effector to target ratio of 2:1. Afterwards cells were analysed by flow 
cytometry for PKH-67/PKH-26 double positive events. Increase in phagocytosis was 
determined and data were transformed to logarithms and fitted to a one site—specific binding 
with hill slope equation in Graph Pad Prism 6. All experiments were performed in technical 
triplicates or quadruplicates and repeated three times. 
Figure 26 illustrates the gating strategy for the evaluation of actively phagocytosed target 
cells by macrophages. First, cells were gated for the PKH-67 positive cell population, which 
represents macrophages. Furthermore, PKH-67 and PKH-26 double positive events were 
gated and quantified, representing macrophages that engulfed one or more cells. In case of 
THP-1 macophages we additionally subgated for CD16 expression (not shown) and 
subsequently analyzed PKH-67 and PKH-26 double positive events. As can be seen in Figure 
26, incubation of target cells with macrophages alone already induces phagocytosis of tumor 
cells at a background level of around 20 %. Thus, an increase in phagocytosis, as percent 
over the background control, was determined as depicted in Figure 27 and Figure 28A and B. 
RESULTS 
 
 
78 
Figure 26 Gating scheme for phagocytosis assay. Cells were first gated for PKH-67+ macrophages and further 
down gated on PKH-67/PKH-26 double positive events. These events represent macrophages that have actively 
engulfed a PKH-26 stained target cell. As shown exemplary, incubation of target cells with macrophages but no 
protein already leads to a background phagocytosis of around 20 %, whereas incubation with protein leads to a 
phagocytosis of around 35 %.  
Figure 27A shows that analysis of the total THP-1 macrophage population for phagocytosis 
of target cells results in highest increase in phagocytosis by incubation with SirpIg_CV1 only 
and SirpIg only (black dashed curves, filled and empty circles). Incubation with 
SirpIg_CV1.αCD16.αCD33 yields in the third highest increase in phagocytosis. However, as 
indicated by the dotted black line in the dose-response curve, the control molecule already 
induces a fairly high unspecific background phagocytosis rate, thus, we could not detect 
phagocytosis above the background for the rest of the liCAD molecules.  
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Figure 27 Phagocytosis assay of THP-1 cells with THP-1 macrophages. (A) Total THP-1 macrophages were 
analysed for phagocytosed target cells upon liCAD incubation. Single domain SirpIg_CV1 and SirpIg only 
(both black dashed curves) induce phagocytosis to a higher extend than SirpIg.αCD16.αCD33 (red curve), 
SirpIg.SirpIg.αCD16.αCD33 (orange curve), αCD47.αCD16.αCD33 (light grey curve) and αCD33.αCD16 
(black curve). Only the high affinity liCAD SirpIg_CV1.αCD16.αCD33 (dark grey curve) shows an increase in 
phagocytosis that is above unspecific background phagocytosis (black dotted curve). (B) Analysis of CD16+ 
THP-1 macrophages shows a lower unspecific activation of macrophages (black dotted curve). Again 
SirpIg_CV1.αCD16.αCD33 (dark grey curve), SirpIg_CV1 only and SirpIg only (both black dashed lines) yield 
in higher increase in phagocytosis compared to SirpIg.αCD16.αCD33 (red curve), SirpIg.SirpIg.αCD16.αCD33 
(orange curve), αCD47.αCD16.αCD33 (light grey curve) and αCD33.αCD16 (black curve) (C) To verify that 
active phagocytosis was determined, 4 °C control reactions and macrophages incubated with beads were 
measured without protein and maximal protein amount. Mean values out of two experiments are shown.  
We determined that only around 5% of THP-1 macrophages expressed CD16 on their cell 
surface (data not shown). Consequently, we subgated macrophages on CD16 expression and 
analysed the increase of phagocytosis in CD16+ THP-1 macrophages. In contrast to the total 
THP-1 macrophage analysis, unspecific phagocytosis induced by the control molecule is 
clearly diminished however, still present starting at a concentration of 10 nM (Figure 27B, 
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dotted black curve). Again SirpIg_CV1 only as well as SirpIg only (black dashed curves, 
filled and empty circles) yield in a higher increased phagocytosis rate of target cells 
compared to SirpIg.αCD16.αCD33 (red curve), SirpIg.SirpIg.αCD16.αCD33 (orange curve) 
and αCD47.αCD16.αCD33 (light grey curve). The high affinity liCAD 
SirpIg_CV1.αCD16.αCD33 (dark grey curve) showes in turn best performance compared to 
the lower affinity liCADs and similar results to SirpIg_CV1 only. Surprisingly, the bispecific 
control liCAD αCD33.αCD16 (black curve) yields in an increased phagocytosis of THP-1 
cells between the trispecific liCADs and the single domain SirpIg variants, which lead us to 
the conclusion that this cell line based phagocytosis assay might not be a proper model 
system to mimic the activity of primary macrophages.  
Therefore, we next established a phagocytosis assay with primary M2 macrophages that were 
incubated with MOLM-13 cells as targets. As shown in Figure 28A, 
SirpIg.SirpIg.αCD16.αCD33 is indeed able to block the Sirp α-CD47 immune checkpoint 
and an increase in phagocytosis can be observed compared to a bispecific control liCAD 
αCD33.αCD16. Though, SirpIg.αCD16.αCD33 seems not to be sufficient in inhibiting the 
“Don`t eat me” signaling, since both bispecific liCAD and SirpIg.αCD16.αCD33 have 
almost overlaying dose response curves. We further tested, weather blockade of Sirp α-CD47 
interaction would be sufficient to induce phagocytosis in primary M2 macrophages, but no 
phagocytosis was observed in this case. Thus, we could demonstrate that on one site an 
activating signal via Fc gamma receptors is necessary to induce phagocytosis but on the other 
site, Fc gamma rezeptor binding only is not suffiecient to induce unspecific activation of 
macrophages, as can be seen by the control construct αHer-2.αCD16.αHer-2. Furthermore, 
control molecules SirpIg_CV1.αCD16.αCD33 and αCD47.αCD16.αCD33 showed expected 
behaviour in phagocytosis assays, as the high affinity SirpIg_CV1.αCD16.αCD33 is the 
strongest inducer of phagocytosis and the rather weak binding αCD47.αCD16.αCD33 
molecule shows similar induction potential to SirpIg.αCD16.αCD33.  
Since most of the pre-existing studies on CD47 blockade by the Weissman group were 
carried out using an αCD47 mAB, we compared the liCAD molecules to the same clone 
called B6H12 which they used in their studies. As demonstrated in Figure 28B liCADs are 
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far better inducers of phagocytosis, however, a combination of αCD47 mAB and a second 
αCD33 mAB would have to be tested in order to correlated and compare biological 
activities.  
Figure 28 Phagocytosis assay of MOLM-13 target cells with primary M2 macrophages. (A) All liCAD 
molecules were tested for their ability to induce phagocytosis. SirpIg.αCD16.αCD33 induces similar 
phagocytosis rates compared to the bispecific control αCD33.αCD16, indicating that low affinity blockade of 
the Sirp α-CD47 interaction does not increase phagocytosis in macrophages. The SirpIg.SirpIg.αCD16.αCD33 
molecule increases phagocytic uptake of target cells in macrophages. SirpIg_CV1.αCD16.αCD33 shows 
highest ability to induce phagocytosis and αCD47.αCD16.αCD33 exhibits similar phagocytosis rates as 
SirpIg.αCD16.αCD33. SirpIg only and the control molecule αHer-2.αCD16.αHer-2 do not induce 
phagocytosis. (B) The mAB αCD47 (B6H12) was compared to liCADs and showed far less phagocytosis 
induction potential. Incubation of macrophages and target cells with SirpIg_CV1 only together with the 
bispecific liCAD αCD33.αCD16 does not rescue induction of phagocytosis. (C) In order to verify that active 
phagocytosis was determined, 4 °C control reactions, Cytochalasin D pre-treated macrophages and 
macrophages incubated with beads were measured without protein (0 nM) and maximal protein amount (100 
nM). One representative experiment is shown out of three.  
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In order to exclude measurements of adhesion artefactions, like target cells not engulfed by 
macrophages but just sticking to the outside of a macrophage and therefore, generating a 
PKH-67/PKH-26 double positive event, a 4 °C control reaction and a reaction with 
Cytochalasin D pre-treated macropahges were carried out in parallel. Cytochalasin D inhibits 
actin polymerization preventing phagocytosis ability of macrophages, which holds also true 
for macrophages kept a 4 °C. As shown in Figure 27C as well as Figure 28C, phagocytosis 
was inhibited at 4 °C and in assays with cytochalasin D pre-treated macrophages (Figure 28C 
only). We thus conclude that the increase in phagocytosis is not caused by an adhesion 
artefact. Additionally, polystyrene beads, a commonly known inducer of phagocytosis, were 
used as a positive control. Incubation with and without protein further demonstrates that 
binding of Fc gamma receptor does not unspecifically increase phagocytosis of beads (Figure 
27C and Figure 28C).  
4.8.4. Preferential killing of CD33 Flp-INTM 293 HEK cells  
Studies on blocking CD47 have pointed out the beneficial effects in tumor cell erradication 
but due to the ubiquitous expression of CD47 on human cells, systemice blockade might lead 
to severe side effects. Thus it is of particular importance to show that liCAD molecules 
preferentially induce killing of CD47/CD33 double positive cells even in the presence of 
CD47 single positive cells. In order to address this crucial question we set out to establish an 
in vitro redirected cytotoxicity assay. A CD33 expressing, stably transfected Flp-INTM 293 
HEK cell line was generated by Monika Herrmann and kindly provided for this study. Since 
CD47 was not manipulated, untransduced Flp-INTM 293 HEK cells could be used as single 
positive and CD33 Flp-INTM 293 HEK cells as double positive target cells, with both cell 
types having same CD47 levels. 
Single and double positive cells were mixed in a 1:1 ratio and incubated with NK cells in an 
effector to target cell ratio of 2:1 for 4 hours. Two reactions were set up in parallel, one 
having single positive cells calcein labeled and the other one having the double positive cell 
fraction calcein labeled. Assays were set up either with increasing protein concentrations 
leading to dose-response curves, or determined protein concentrations, leading to maximal 
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and half maximal effective response, respectively. All experiments were performed in 
technical triplicates and repeated three times. 
Figure 29 illustrates dose response curves of preferential killing assays showing specific lysis 
of CD47 single positive Flp-INTM 293 HEK cells in panel A and specific lysis of CD47/CD33 
double positive cells in panel B.  
Figure 29 Dose response curves of preferential killing assays. (A) % specific lysis of CD47 single positive 
Flp-INTM 293 HEK cells is shown for all tested liCADs. SirpIg.αCD16.αCD33 (red curve) and 
SirpIg.SirpIg.αCD16.αCD33 (orange curve) have higher EC50 values compared to CD47 high affinity 
molecules SirpIg_CV1.αCD16.αCD33 (dark grey curve) and αCD47.αCD16.αCD33 (light grey curve), 
indicating worse targeting and therefore the ability of avoiding systemic binding of CD47. (B) % specific lysis 
of CD33 Flp-INTM 293 HEK cells is shown for all tested liCADs. Error bars represent standard error of the 
mean of triplicates. 
SirpIg.αCD16.αCD33 (red curves) has an EC50 of 567 pM (95% CI = 5.1 pM-62 nM) for 
single positive cells compared to 9 pM (95% CI = 4.5 pM-17 pM) for double positive cells, 
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indicating that SirpIg within the liCAD does not sufficiently target cells and therefore, is 
likely not to bind systemically to the ubiquitously expressed CD47 surface antigen. The same 
holds true for SirpIg.SirpIg.αCD16.αCD33 (orange curves) that shows EC50 values of 97 pM 
(95% CI = 0.2 pM-36.7 nM) in case of single positive cells versus 0.7 pM (95 CI = 
0.17 pM-2.6 pM) for CD33 Flp-INTM 293 HEK cells. SirpIg_CV1.αCD16.αCD33 (dark grey 
curves) has a half maximal effective concentration at 0.5 pM (95% CI = 0.2 pM-1.4 pM) for 
CD47 expressing cells and at 0.1 pM (95% CI = 0.065 pM-0.25 pM) for CD47/CD33 
expressing cells. The control triplebody αCD47.αCD16.αCD33 (light grey curves) also 
exhibits very comparable EC50 values between both cell types (14 pM (95% CI = 
1.8 pM-109 pM) for single positive cells versus 9 pM (95% CI not determinable) for double 
positive cells). These data point out the advantage of a low affinity-binding to CD47 against 
systemic high-affinity binding. The application of low affinity liCADs in cytotoxicity assays 
reveals a therapeutic window that gives reason to hope for a therapeutic response on tumor 
cells without causing seriouse damage to healthy tissue.  
To strengthen the potential of liCAD molecules to preferentially kill CD47/CD33 double 
positive tumor cells but not CD47 single positive cells, Figure 30 shows results for obtained 
data with maximal protein concentrations used.  
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Figure 30 Maximal effective concentration of liCAD proteins analysed in preferential killing assays. 
SirpIg.αCD16.αCD33 (red) and SirpIg.SirpIg.αCD16.αCD33 (orange) demonstrate significant preferential 
lysis of CD33 Flp-INTM 293 HEK cells over Flp-INTM 293 HEK cells when incubated at maximal effective 
concentration. SirpIg_CV1.αCD16.αCD33 (dark grey) as well as αCD47.αCD16.αCD33 (light grey) induce 
lysis of both cell types to the same extent. Bispecific liCADs αCD33.αCD16 (black) and SirpIg.αCD16 
(black/grey stipped) served as controls. Error bars represent standard error of the mean of triplicates. 
The results affirm impressively that SirpIg.αCD16.αCD33 (red bar, 20 nM used) as well as 
SirpIg.SirpIg.αCD16.αCD33 (orange bar, 10 nM used) significantly preferentially kill 
CD33 Flp-INTM 293 HEK cells (Sirp.αCD16.αCD33 p = 0.0041, 
SirpIg.SirpIg.αCD16.αCD33 p = 0.0006). The high affinity liCAD 
SirpIg_CV1.αCD16.αCD33 (dark grey bar, 1 nM used) as well as the triplebody 
αCD47.αCD16.αCD33 (light grey bar, 20 nM used) both kill single and double positive Flp-
INTM HEK cells to the same extent, thus, no significant differences could be detected. As 
expected the bispecific control molecule αCD33.αCD16 (black bar, 100 nM used) only 
shows killing in CD33 Flp-INTM HEK cells. SirpIg.αCD16 (black/grey stripped bar, 100 nM 
used), which lacks any tumor antigen-targeting domain, did not show any killing feature.  
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In order to obtain comparable specific lysis values, we decided to compare killing at half 
maximal effective dose concentrations of all proteins, as shown in Figure 31.  
Figure 31 Half maximal effective concentration of liCAD proteins analysed in preferential killing assays. 
SirpIg.αCD16.αCD33 (red), SirpIg.SirpIg.αCD16.αCD33 (orange) and SirpIg_CV1.αCD16.αCD33 (dark 
grey) reveal significant preferential lysis of CD47/CD33 double positive cells. αCD47.αCD16.αCD33 (light 
grey) induce lysis of both cell types to the same extent. Bispecific liCADs αCD33.αCD16 (black) and 
SirpIg.αCD16 (black/grey stipped) served as controls. Error bars represent standard error of the mean of 
triplicates 
SirpIg.αCD16.αCD33 (red bar) as well as SirpIg.SirpIg.αCD16.CD33 (orange bar) 
significantly preferentially kill CD33 Flp-INTM 293 HEK cells (Sirp.αCD16.αCD33 p = 
0.0091, SirpIg.SirpIg.αCD16.αCD33 p = 0.0009), interestingly at this lower protein 
concentration also SirpIg_CV1.αCD16.αCD33 (dark grey bar) showed a significant killing 
in CD47/CD33 double positive cells (p = 0.0087). The control triplebody 
αCD47.αCD16.αCD33 (light grey bar) however, killed CD47 single positive cells to a 
similar extent than CD47/CD33 double positive cells. The bispecific control αCD33.αCD16 
(black bar) points out an unspecific background killing of CD47 single positive Flp-INTM 293 
HEK cells of around 10 %, which has to be taken into consideration for data obtained with all 
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other liCAD molecules. SirpIg.αCD16 (black/grey stipped bar) shows, as expected, similar 
killing potential for both cell types.  
Next, we wanted to translate gained knowledge of liCAD potential from the Flp-INTM 293 
HEK cell line model system to AML tumor cell lines. Therefore we used MOLM-13 cells 
that express high levels of CD33 and OCI-AML3 cells, which express low levels of CD33. 
Both cell lines express comparable amount of CD47 on their surface. All experiments were 
carried out as described above for Flp-INTM 293 HEK cell lines.  
Figure 32 Preferential killing assays of MOLM-13 and OCI-AML3 cells. Same tendencies for all liCAD 
molecules can be seen with (A) maximal protein concentrations as well as (B) half maximal effective protein 
concentrations. Bispecific liCADs αCD33.αCD16 (black) and SirpIg.αCD16 (black/grey stipped) served as 
controls. Error bars represent standard error of the mean of triplicates. 
Figure 32A and Figure 32B illustrate data obtained for maximal and half maximal effective 
liCAD concentrations used, respectively. In both experimental set-ups only slight differences 
between specific lysis of OCI-AML3 cells and MOLM-13 cells can be seen. However, 
SirpIg.αCD16.αCD33 (red bar) and SirpIg.SirpIg.αCD16.αCD33 (orange bar) again reveal a 
higher tendency to induce preferential killing of CD33 high expressing MOLM-13 cells, 
especially when used at maximal protein concentrations. SirpIg_CV1.αCD16.αCD33 (dark 
grey bar) as well as αCD47.αCD16.αCD33 (light grey bar) show in both cases same 
potential to kill either target cell. Bispecific control constructs αCD33.αCD16 (black bar) 
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and SirpIg.αCD16 (black/grey stripped bar) demonstrate expected killing behavior. 
αCD33.αCD16 induces killing of MOLM-13 cells better due to higher CD33 expression 
levels whereas SirpIg.αCD16 induces specific lysis of both cell types to a similar extent 
explained by comparable CD47 expression levels. 
4.8.5. NK cell mediated lysis of AML patient blast samples 
All performed assays were testing the biological activity of liCADs in tumor cell lines that 
are easier to maintain and represent a good model to demonstrate efficacy. For the validation 
of these preceding results, our collaboration partner Prof. Marion Subklewe checked for 
liCAD-induced cytotoxicity of primary AML patient cell samples.1  
A FACS based NK cell mediated cytotoxicity assay was performed as described in detail in 
the section “material and methods”. Cells were analysed on day 0 and incubated 
subsequently for 24 hours with SirpIg.SirpIg.αCD16.αCD33 liCAD, bispecific control 
αCD33.αCD16 and without antibody to account for the negative control. Experiments were 
performed 3 times with various AML patient samples.  
Figure 33A illustrates the proportion of CD33+ remaining cells expressed as percentage of 
the control condition incubated without liCAD. We show that SirpIg.SirpIg.αCD16.αCD33 
(orange bar) induces stonger NK cell mediated killing of AML patient cells in contrast to the 
bispecific control αCD33.αCD16 (black bar). As shown in Figure 33B, analysis of the mean 
fluorescence intensity of CD16 expression on NK cells reveals a higher downregulation of 
the receptor upon liCAD binding (green histrogram) compared to the αCD33.αCD16 (blue 
histogram) and the negative control (red histogram). Downregulation of CD16 is in concert 
with NK cell activation. Thus, we hypothesize that the observed increased killing potential of 
NK cells is due to higher activation, which might be accomplished by additional CD47 
ligation. The gating of NK cells and AML cells at different effector to target ratios is 
illustrated exemplary in Figure 33C.  
                                                
1 All experiments were executed and analysed in the laboratory of Prof. Subklewe by 
Christina Krupka and data were kindly provided for this PhD study. 
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Figure 33 NK cell mediated cytotoxicity of AML patient samples. (A) Analysis of remaining CD33+ cells. 
SirpIg.SirpIg.αCD16.αCD33 (orange) shows higher killing potential compared to the bispecific control 
αCD33.αCD16 (black). (B) Exemplary illustration of the mean fluorescence intensity of CD16 expression. 
Upon binding to a liCAD molecule a stronger downregulation of the receptor is detected. (C) Gating of 
CD16+/CD56+ NK cells and CD33+ AML blasts shows higher decrease of AML cells in case of 
SirpIg.SirpIg.αCD16.αCD33 compared to the bispecific control αCD33.αCD16 at any E:T ratio. Incubation of 
NK cells and blasts with no antibody was used as a control. Error bars represent standard error of the mean of 
triplicates. 
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5. DISCUSSION 
Immunotherapy has revolutionized cancer treatment. The advent of immune checkpoint 
inhibitors in particular caused excitement within the scientific community and provided hope 
to combat difficult-to-treat cancer types, such as acute myeloid leukemia (AML). The CD47-
Sirp α interaction, also referred to as “Don’t eat me” signal, is a long underestimated immune 
checkpoint that regulates phagocytic activity of macrophages and dendritic cells. In AML it 
has been shown that there is higher expression of CD47 in the leukemic stem cell (LSC) 
compartment than in normal hematopoietic stem cells (HSCs), and that increased expression 
of CD47 is a poor prognostic factor (Majeti et al., 2009). Blocking of CD47 in combination 
with targeting a tumor antigen using mAbs has been shown to improve tumor eradication in a 
non-Hodgkin lymphoma (NHL) mouse model (Chao et al., 2010). Thus, this might be a 
promising strategy to follow up in AML, where novel therapies with higher efficacy and 
lower toxicity are strongly needed for treatment.  
The myeloid surface antigen CD33 is a meanwhile well-established tumor target in AML 
therapies and there are still good prospects that it will be used in the future. The first trial 
with an anti-CD33 mAb in AML therapy was performed 20 years ago (Scheinberg et al., 
1991). In the year 2000 the Food and Drug Administration (FDA) approved the anti-CD33 
immunoconjugate drug gemtuzumab ozogamicin. Due to concerns about toxicity and lack of 
efficacy it was withdrawn from the market, however, it has been shown in various studies 
that lower doses of the drug (3-6 mg/m2 instead of 9 mg/m2) as well as different 
administration strategies (either single dose or fractionated) are safe and also effective. 
Krupka et al demonstrated that AMG 330, a CD33/CD3 bispecific T-cell engager (BiTE), 
preferentially kills LSCs that have higher levels of CD33 expression than HSCs and therefore 
allows for restoration of normal hematopoiesis (Krupka et al., 2014).  
The aim of this thesis was to generate a novel trispecific antibody (tsAb) format that, similar 
to BiTEs, recruits effector cells to CD33 expressing AML cell lines, blasts or LSCs and 
additionally blocks the CD47-Sirp α interaction. To this end, we used the naturally occurring 
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extracellular domain of Sirp α and linked it to an effector cell recruiting CD16 singel chain 
fragment variable (scFv) and a tumor cell recruiting CD33 scFv.  
5.1. Generation and expression of liCADs, a novel trispecific antibody format 
The major task of this study was to design, express and purify a novel antibody format, 
which we termed local inhibitory checkpoint antibody derivative (liCAD). The main 
advantage of this novel format is the local bloackade of CD47 at the tumor side, rather than a 
systemic blockade of the ubiquitously expressed antigen. By using the extracellular domain 
of Sirpα, we hypothesize that our liCAD molecule would not bind systemically to CD47 
positive cells but rather to CD33 as well as strongly overexpressing CD47 tumor cells, 
possibly circumventing severe side effects. We designed constructs bearing the total 
extracellular domain of Sirp α (referred to as Sirp ex) as well as only the N-terminal Ig-like 
V type domain (referred to as SirpIg), which was shown to be sufficient for binding to CD47 
(Hatherley et al., 2008). Single domain expression in E. coli BL21 cells revealed that Sirp ex 
was highly unstable and was partly degraded to SirpIg. This led us to the decision to conduct 
further experiments and analysis solely with the N-terminal Ig-like V type domain SirpIg.  
SirpIg.αCD16.αCD33 and SirpIg.SirpIg.αCD16.αCD33 were expressed in the well-
established human FreeStyleTM 293-F cell system. Proteins were secreted into the cell culture 
supernatant due to an Igκ leader sequence within the expression vector. A straightforward 
purification strategy comprising anion-exchange chromatography and size-exclusion 
chromatography was subsequently used and resulted in pure protein. To validate the 
beneficial use of the low affinity SirpIg domains we had to generate control constructs, 
which bind to CD47 with a higher affinity. Therefore, we designed constructs comprising a 
published high affinity mutant of SirpIg, called SirpIg_CV1 (Weiskopf et al., 2013) and a 
scFv against CD47. Extensive attempts to express and purify these control molecules in 
human FreeStyleTM 293-F cells failed. We realized that not the expression itself but, due to 
the high affinity to CD47, the proteins were immediately bound to the FreeStyleTM 293-F cell 
surface. Attempts to dissociate liCADs from the cell surface by using detergent or pH 
changes failed due to the high affinity interaction. One way to prevent the binding of the 
proteins to CD47 on the FreeStyleTM 293-F cells is to knockdown or ideally knockout CD47 
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expression. We performed a partial knockdown using an ON-TARGET plus siRNA 
SMARTpool directed against CD47 in parallel to transient transfection of the desired liCAD 
protein. By this the amount of purified protein increased, however, the yield was still too low 
to include futher purification steps or biological studies. We could nevertheless show that 
partial knockdown of CD47 still results in viable FreeStyleTM 293-F cells that are capable of 
expressing protein. This result suggests that for future studies it might be an option to 
generate a stable gene knockout of CD47 in FreeStyleTM 293-F cells using, for example, the 
CRISPR/Cas9 genome editing technology. By doing so, the immediate binding of liCADs 
with higher affinity to CD47 would be solved and additionally stable cell lines could be 
generated that increase the protein yield. 
Since the interaction of CD47 and Sirp α is species specific, another possibility to avoid 
protein binding to the cells is to switch to an expression system that is not of human origin. 
During this study we therefore used a Drosophila melanogaster Schneider 2 (S2) expression 
system (ExpreS2ion Biotechnologies). The major difference in expressed proteins between 
human and insect cells lies in the glycosylation pattern. S2 cells have been shown to produce 
paucimannose (MAN-3) N-glycosylations that are shorter compared to mammalian cells 
(Kim et al., 2005). With respect to the influence of glycosylation patterns on biological 
activity, it has been shown for mAbs that, for example, the binding characteristics for IgG1 
of the same clones expressed in S2 cells or mammalian cells were indistinguishable 
(Johansson et al., 2007). In the case of the interaction of CD47 with Sirp α it has been 
reported that N-linked glycosylations of the N-terminal Ig-like V type domain of Sirp α do 
not influence binding behavior (Lee et al., 2007; Subramanian et al., 2006), thus we did not 
expect the altered glycosylation to influence its biological activity. To prove this hypothesis 
we analysed mammalian and insect cell expressed proteins in redirected lysis assays for their 
ability to induce killing of tumor cell lines and could not detect any differences in their 
activity. Furthermore, the Schneider 2 system was reported to be extremely well suited for 
bioproduction. It allows stable, non-lytic, high-level expression of a wide range of 
recombinant proteins, with published yields of 1 g of mAb per liter of culture (Wang et al., 
2012). Stable cell lines for all of the liCADs were generated and these produced, depending 
on individual proteins, approximately 10 mg of liCAD per liter of culture after a four-step 
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purification protocol. S2 cells generally reach cell densities up to 70 million cells/ml, 
compared to 4 million FreeStyleTM 293-F cells/ml, which is one explanation for higher 
protein yields. Due to the composition of the insect cell medium, an initial buffer exchange 
step had to be included in the purification strategy prior to isolation of 6xHis-tagged protein 
with Ni2+-NTA agarose beads, prolonging the purification procedure by one day. To avoid 
this additional step, the S2 cells could be grown in an alternative insect cell media that does 
not interfere with the binding of the His-tag to the Ni2+-NTA agarose beads, although this 
may also alter the protein yield. Another important factor in influencing protein yield is the 
generation of stable cell lines itself. In this PhD thesis polyclonal stable cell lines were 
generated. More protein would be required, however, for the in vivo testing of liCAD 
proteins in mice. In this case, generating monoclonal stable cell lines and screening for the 
highest producer would certainly increase protein yield. For this particular study, however, 
these advantages were outweighed by the disadvantages that this procedure requires a longer 
generation time and additional screening time. 
A crucial factor in the construct design of liCADs is the capture step to first pull down 
proteins from expression supernatants. In contrast to mAbs, which are purified using the Fc 
stem binding protein A, liCADs are not bound by protein A or any other resin frequently 
used in biopharmaceutical industry. Consequently, all liCADs had a N-terminally cloned 
6xHis tag that exhibits a high affinity towards metal ions such as nickel (Ni) and zinc (Zn) 
and enables immobilised metal affinity chromatography (IMAC) to be used as a first 
purification step. The major drawback of using the histidine tag is the low recovery rate of 
protein and purity. This is because naturally occurring metal-binding proteins and the 
presence of histidine- as well as cysteine-rich spots within proteins are able to compete with 
the tagged proteins for the immobilized metal ions. However, several therapeutic candidate 
proteins purified using IMAC, are currently in clinical studies (Angov et al., 2003; Mack et 
al., 1995; Ockenhouse et al., 2006; Stoute et al., 2007).  
5.2. liCADs exhibit low binding affinity to CD47 
We next validated the liCADs as a novel tsAb format for their ability to locally interfere with 
CD47. To this end we used flow cytometry of human cell lines incubated with liCADs. 
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Binding was detected using an anti-His tag antibody. Due to the fact that all human cells 
express CD47 on their surface we could not use them to test for example binding of the anti-
CD33 scFv to the antigen. To rule out additional CD47 binding we had two different 
strategies to follow up. First, we purified all single domains of the liCAD separately so that 
their binding could be characterized. We could not exclude the possibility, however, that the 
KD values determined for individual domains would be representative of the values for the 
domain in the context of the whole liCADs. Additionally, we were unable to detect binding 
of SirpIg to any of the human cell lines tested. The reason for this is the binding affinity of 
SirpIg to CD47, which is reported to be in the high nanomolar (≈450 nM) (Weiskopf et al., 
2013) to low micromolar (≈1.2 μM) (Hatherley et al., 2008) range. This is consequently 
below the detection limit of the method, which depends on several washing steps to remove 
unspecific background signal. The big discrepancy in reported binding affinities highlights 
that measuring low affinity interactions in vitro is in general a challenging task. Furthermore, 
the determined binding affinities might not in any case reflect the situation in vivo.  
The second strategy followed up implied transgenic cell line generation of non-human origin. 
In order to be able to use flow cytometry for binding studies, we generated Chinese Hamster 
Ovary (CHO) cell lines in which either human full length CD47 or human full length CD33 
were highly overexpressed. Thereby we could test for binding of CD33 within the liCAD 
without influence from CD47 and vice versa. By generating these strongly overexpressing 
cell lines, we were also able to detect SirpIg binding to CD47 and calculate KD values for the 
interaction. Even though this is certainly an artificial system with saturated amount of CD47 
on the cell surface, the binding affinities determined for Sirp α are in the range of reported 
measurements by surface plasmon resonance. Although we could not show binding of SirpIg 
to CD47 on human cells, these data support the idea that the SirpIg domain used in this work 
would locally bind to tumor cells overexpressing CD47.  
Consistent with the observation that duplication of low affinity scFvs in diabodies increases 
their functional affinity (= avidity) for the tumor antigen 40-fold (Adams et al., 1998), it was 
not surprising to see that duplication of the SirpIg domain resulted in a 30-fold tighter 
interaction with CD47. This is likely a result of a strong avidity effect that also results in a 
higher biological activity, which we could later show through redirected lysis assays and 
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macrophage assays. The rather low interaction determined for the control triplebody 
αCD47.αCD16.αCD33 might be explained by the composition of the anti-CD47 scFv, which 
only harbors a five amino acid linker between the variable heavy and variable light chains, 
compared to the 25 and 20 amino acid linkers present in the anti-CD16 and anti-CD33 scFvs, 
respectively. It might be that the shorter linker disturbs folding properties of the scFv and 
therefore influences binding affinity. The reason for why this molecule could not be purified 
from FreeStyleTM 293-F cells but SirpIg.SirpIg.αCD16.αCD33 could is still unclear and 
remains to be investigated. 
5.3. liCAD molecules are able to recruit NK cells and induce tumor cell 
cytotoxicity 
After verifying their binding capability we tested the biological activity of the generated 
proteins. LiCADs were designed with a central anti-CD16 scFv that binds to CD16 (also 
known as FcγRIIIa) with a high affinity. CD16 is expressed primarily on all CD56+ 
peripheral blood NK cells and is the best-characterized membrane receptor responsible for 
triggering of lysis (Mandelboim et al., 1999). In this study we performed in vitro cytotoxicity 
assays first using in vitro IL-2 expanded NK cells, which are prestimulated due to the IL-2 
supplementation in the cell culture medium, and subsequently using MACS sorted NK cells. 
The advantage of expanded NK cells is that one can culture millions of cells from one donor, 
freeze them and use them for replicates. Therby less variation between the independent 
experiments, due to lack of donor variations of NK cells is expected. From the point of view 
of NK cell preparation costs it might also be profitable to make a single batch of NK cells 
over 21 days and use them for an ongoing study. The long-time storage of NK cells is not 
recommended, however, as the cell population is very fragile and tends to quickly loose its 
activity potential upon storage. This in turn leads to a decrease in the specific lysis of target 
cells. Interestingly, comparison of the half-maximal effective doses of individual molecules 
between expanded and sorted NK cells revealed that EC50 values were between 5 to 25 times 
lower for MACS sorted NK cells. Consequently, the concentration of liCADs required to 
induce half-maximal specific lysis of the target cells was in every case lower when the 
experiment was performed with freshly prepared MACS sorted NK cells. This might result 
from differences in the CD16 expression level on the NK cells. Thus, our collaboration 
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partner Prof. Marion Subklewe analysed the CD16 expression on IL-2 expanded NK cells 
using flow cytometry and showed that CD16 expression is indeed reduced with respect to 
MACS sorted cells. These data certainly contribute to the observation that expanded NK cells 
stored in liquid nitrogen loose their activation potential over time. Therefore, we conclude 
that according to reliability of results concerning liCAD potential to recruit and induce 
effector cells, IL-2 expanded NK cells are definitely comparable to freshly prepared 
NK cells. It has to be kept in mind that the accuracy of half maximal effective dose estimates 
is affected by the long-time storage of expanded NK cells, because this results in a lower 
activation potential and higher EC50 values compared to MACS prepared NK cells. 
For assays with IL-2 expanded NK cells we could show that SirpIg.αCD16.αCD33 as well as 
SirpIg.SirpIg.αCD16.αCD33 had an increased potential to induce specific lysis of the AML 
cell line MOLM-13 compared to the bispecific control αCD33.αCD16. This would be 
consistent with the dual targeting effect of liCAD molecules or possibly an additive 
prostimulatory effect on NK cells. Tighter interaction of Sirp α to CD47 correlated with an 
increased potential to induce specific lysis. To rule out the possibility that the apparent 
activation potential of liCADs is only due to prestimulation of NK cells, we performed the 
same assays using primary MACS sorted NK cells. Similarly, we could demonstrate the 
same tendency in activation potential in primary MACS sorted NK cells. Additionally, we 
verified the observed cytotoxicity potential of highly expressing CD33 AML cells in a lowly 
expressing CD33 AML cell line, OCI-AML3 (around 30000 molecules per MOLM-13 cell 
versus around 3000 molecules per OCI-AML3 cell). We obtained very similar values for 
half-maximal effective doses of individual liCAD molecules. Subsequently we analyzed the 
number of CD47 molecules on MOLM-13 and OCI-AML3 cells and obtained comparable 
values (around 40000 molecules per MOLM-13 cell versus around 50000 molecules per 
OCI-AML3 cell). Therefore, the data cannot be explained by increased CD47 expression on 
OCI-AML3 cells compensating for decreased CD33 expression. The minor killing potential 
of SirpIg.αCD16 in both experiments indicates the non-targeting property of the SirpIg 
domain alone, due to its low affinity for CD47. For the bispecific control αCD33.αCD16 we 
demonstrate that the more CD33 is expressed on the tumor cell the better killing is induced. 
However, liCADs have regardless of CD33 antigen expression very similar induction 
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potential. Consistent with these observations we have come up with two different hypotheses. 
The first is that liCADs induce a dual targeting effect, but only upon bringing the effector 
cell into close proximity to the tumor cell. The second, more likely, possibility is, that 
crosslinking of the NK cell with the target cell leads to either a co-stimulatory effect on the 
NK cell or a pro-apoptotic stimulus on the tumor cell via CD47 binding. Our second 
hypothesis is supported by literature because, at least for T cells, it has been shown that 
CD47 binding (via Sirp α on DCs or mABs) has a co-stimulatory effect on T cell activation 
(Reinhold et al., 1997; Seiffert et al., 2001). Furthermore, in a multiple melanoma cell model 
it has been reported that anti-CD47 scFvs induce apoptosis of tumor cells (Kikuchi et al., 
2005). Therefore, further experiments analyzing NK cell activation markers, such as 
CD107a, or apoptosis markers, such as annexin V, will have to be performed. Additionally, 
cytotoxicity assays using target cells that do not express CD47 will need to be performed to 
clarify if SirpIg within the liCAD acts on the target cell or on the NK cell. Through this one 
could determine if the obtained specific lysis of target cells incubated with the bispecific 
control SirpIg.αCD16 is tumor cell related or due to a co-stimulatory activation of NK cells. 
We also performed effector to target cell ratio titrations to shed light on the potential of 
liCADs to induce serial lysis of effector cells. We saw that the specific lysis of MOLM-13 
cells decreased with decreasing effector to target ratios. This indicates that liCADs may not 
have the potential to induce serial killing of tumor cells by NK cells. In contrast to cytotoxic 
T cells, it might be the case that only IL-2 stimulated, pre-activated NK cells are capable of 
serial killing, as previously reported in literature (Bhat and Watzl, 2007).  
5.4. LiCADs increase phagocytic uptake of tumor cells in macrophages 
A major goal of this thesis was to determine the ability of SirpIg to block the naturally 
occurring CD47-Sirp α interaction inducing phagocytosis in macrophages. In order to avoid 
donor-specific variations, which could easily lead to diverse results, we first wanted to 
establish a cell line based assay that facilitates on one hand reproducibility and on the other 
hand faster excess to macrophages. Furthermore, working in an autologous setting is always 
preferred to an allogeneic setting, since background phagocytosis may be reduced. We 
therefore made use of the possibility to differentiate THP-1 cells to macrophages and 
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incubate them together with undifferentiated THP-1 cells. However, sustained results showed 
an unusual strong unspecific increase in phagocytosis and an especially high increase in 
phagocytosis by blocking only the CD47-Sirp α interaction. We also realized that THP-1 
macrophages express very little CD16 on their surface, which makes them also a poor model 
system to test molecules containing an anti-CD16 scFv as an effector-recruiting domain.  
We consequently switched to primary monocytes that we differentiated to M2 macrophages, 
which are commonly known as the CD16 expressing subset of macrophages (Italiani and 
Boraschi, 2014). Incubation of macrophages with SirpIg.SirpIg.αCD16.αCD33 effectively 
increased phagocytic uptake of MOLM-13 cells in all experiments, however 
SirpIg.αCD16.αCD33 showed only a slight increase compared to the bispecific control 
αCD33.αCD16. This was certainly also donor related since some macrophages responded 
with larger increase and other with same increase rates as the control. In contrast to the cell 
line based system, we did not see an increase in phagocytosis induced by the SirpIg domain 
alone. This is in agreement with the literature, which reports that Sirp α blockade alone is not 
sufficient to induce phagocytosis (Weiskopf and Weissman, 2015). Even though M2 
macrophages are known to be the CD16 expressing subpopulation, we aimed to analyse only 
CD16+ cells by flow cytometry. We included a CD16 staining step in our analysis, but were 
only rarely able to detect CD16+ events. The reason for this might be the internalization of 
the CD16 receptor on the surface of macrophages upon ligation. In control wells, where we 
did not add liCAD protein, we could detect CD16 expression. As soon as we added liCAD, 
however, CD16 expression was hard to detect. Thus, we were not able to obtain reliable data 
sets and did not include these data in our evaluation. In order to limit analysis to CD16 
expressing macrophages, an intracellular staining of CD16 would have to be performed. 
However, we aimed to avoid the intracellular staining of macrophages since it is a time-
demanding procedure and includes fixation and permeabilization steps that might cause 
artefacts in the assay. 
As most of the studies carried out by the Weissman group demonstrated a beneficial effect of 
the blockade of CD47 in tumor cell phagocytosis, we included the same clone they used for 
blocking (B6H12) in our assays to approximately correlate our liCADs with the mAb. Again, 
we could show that SirpIg.SirpIg.αCD16.αCD33 performed better than the anti-CD47 mAb 
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B6H12, which is however unsurprising since the liCAD molecule combines tumor cell 
targeting and checkpoint inhibition. It would therefore be better to compare liCADs with a 
combination of two mAbs, one that targets in our case CD33 and the other one that blocks 
the CD47 interaction.  
5.5. LiCADs preferentially kill CD47/CD33 positive tumor cells  
CD47 is expressed ubiquitously on all cells of the human body, which increases the 
likelihood of side effects if it is targeted. However, since the CD47 binding component in the 
liCAD molecule is the naturally occurring extracellular domain of Sirp α, which only weakly 
interacts with CD47, we hypothesize that liCAD molecules would preferentially target tumor 
cells that express CD33 but not other non-CD33 expressing cells.  
Thus, we performed a cytotoxicity assay with a mixed target cell population of CD47 single 
positive and CD47/CD33 double positive cells. To this end, we made use of the Flp-INTM 293 
HEK cell system, which enabled us to stably integrate full length human CD33. Since those 
cells are of human origin they express CD47, which is thus also expressed on untransduced 
cells. Analyzing dose response curves we could demonstrate that the CD47 control liCADs 
SirpIg_CV1.αCD16.αCD33 and αCD47.αCD16.αCD33 killed both cell populations to a 
very similar extent. In contrast, SirpIg.SirpIg.αCD16.αCD33 and SirpIg.αCD16.αCD33 had 
far higher half maximal effective dose values for Flp-INTM 293 HEK cells compared to CD33 
Flp-INTM 293 HEK cells. This indicates, that at same concentrations, we induce in case of 
SirpIg.αCD16.αCD33 63-times higher and in case of SirpIg.SirpIg.αCD16.αCD33 even 
more impressively, 138-times higher specific lysis of CD33 Flp-INTM 293 HEK cells 
compared to Flp-INTM 293 HEK cells. We suggest this range as the therapeutic window in 
which the liCAD produces a therapeutic response without causing significant side effects in 
patients.  
To confirm these data we performed additional cytotoxicity assays using either the maximal 
or half maximal effective concentrations of individual liCADs with Flp-INTM 293 HEK cells 
or, in a less artificial system, a mixture of MOLM-13 and OCI-AML3 cells. With the Flp-
INTM 293 HEK cells we could again verify the preferential killing potential of low affinity 
liCADs SirpIg.αCD16.αCD33 as well as SirpIg.SirpIg.αCD16.αCD33. Both preferentially 
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killed CD33 Flp-INTM 293 HEK cells whereas the CD47 control liCADs did not, at least at 
the maximal effective concentrations used. In experiments carried out with the half maximal 
effective concentrations of liCADs we observed a background killing of Flp-INTM 293 HEK 
cells of around 10% that was visualized by the bispecific control αCD33.αCD16, which 
should not target CD33 negative cells. These results might be explained by variations in NK 
cell donors. 
In order to translate the beneficial effect of liCADs from HEK cells to tumor cell lines, we 
performed cytotoxicity assays using MOLM-13 cells that highly express CD33 and OCI-
AML3 cells that express CD33 at a low level. Even though both cell lines express CD33, we 
could observe that the higher expressing cell line, MOLM-13, was preferentially killed. We 
could not detect as many differences as in case of the Flp-INTM 293 HEK cell system but, due 
to the mentioned CD33 expression levels as well as differences in CD47 expression, this was 
expected.  
Taken together, we observed the huge and very impressive potential of our novel liCAD 
format to preferentially kill CD47/CD33 double positive cells in in vitro cytotoxicity assays, 
which puts hope into further clinical use of these molecules. We suggest that these trispecific 
Abs have a beneficial outcome and display decreased side effects compared to antibodies that 
target CD47 with high affinity. 
5.6. LiCADs induce NK cell mediated killing of primary AML patient samples 
We successfully demonstrated the potential of liCADs to induce effector cell mediated 
killing of various tumor cell lines as well as non-tumor cell lines, which indicates there may 
also be a high possibility of cytotoxicity behavior when used with AML patient samples. In 
order to confirm this hypothesis, our collaboration partner Prof. Marion Subklewe performed 
in vitro NK cell mediated cytotoxicity assays with primary AML patient cells. Her research 
group previously showed that CD33 expression on AML blasts is highly diverse (Krupka et 
al., 2014), which certainly influences outcome of mAb therapy. It was also shown that CD47 
is highly overexpressed on AML blast samples compared to healthy hematopoietic cells 
(unpublished data), which is consistent with published data from the Weissman group 
(Majeti et al., 2009).  
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We could show that incubation of AML blasts with SirpIg.SirpIg.αCD16.αCD33 induced 
stronger NK cell mediated killing of blasts after 24 hours when compared to the bispecific 
control αCD33.αCD16. Furthermore, we observed a stronger downregulation of CD16 on 
the NK cells after SirpIg.SirpIg.αCD16.αCD33 incubation, which is indicative of stronger 
NK cell activation. At present we cannot rule out that the detected CD16 downregulation is 
due to an overlap of the binding epitopes of the anti-CD16 scFv and FACS antibody used. 
Though, the differences in mean fluorescence intensity of CD16 expression between NK 
cells incubated with SirpIg.SirpIg.αCD16.αCD33 and αCD33.αCD16 speak against this 
possibility. Certainly further investigations are necessary to verify these first hints on 
increased NK cell activation, like interferon γ secretion or staining for the activation marker 
CD107a. In addition to SirpIg.SirpIg.αCD16.αCD33, we will also test SirpIg.αCD16.αCD33 
for killing and NK cell activation potential. Nevertheless, we are confident that the novel 
liCAD format has the potential to induce NK cell mediated killing of AML patient cell 
samples in vitro by improved NK cell activation compared to the bispecific molecule that 
does not have the SirpIg domain. Thus, these data strongly support our hypothesis about the 
increased NK cell activation by the SirpIg-CD47 interaction. However, we will have to rule 
out unspecific NK cell activation caused by CD47 ligation, since this would probably lead to 
undesired side effects and damage of healthy tissue, respectively.  
5.7. Future directions for liCAD molecules 
During this study we successfully demonstrated that the simultaneous targeting of CD33 on 
tumor cells and blockade of the CD47-Sirp α interaction results in increased effector cell 
functions in NK cells as well as macrophages. All of our performed experiments were in 
vitro studies thus in vivo efficacy must be tested. To date, a routinely used preclinical test of 
a new compound includes injections into animals. In the case of liCADs it certainly is very 
challenging to find a relevant mouse model, since the CD47-Sirp α interaction is species 
specific and a molecule targeting human antigens consequently cannot interact with mouse 
CD47. One of the main questions important to ask, that is to say the question about side 
effects due to ubiquitous expression of CD47, can therefore not be addressed by the accepted 
transplantable as well as spontaneous tumor mouse models. Therefore, one possibility would 
be to generate a CD47 humanized immunodeficient mouse, which is certainly challenging. 
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Cynomolgus monkeys could alternatively be used instead of mouse models. In a pre-clinical 
study it has been shown that a humanized anti-CD47 mAb was able to bind do monkey CD47 
(Liu et al., 2015). For in vivo studies in general, half-life of liCAD proteins would have to be 
analysed, which might be optimized by different buffer formulations. Thus long-term 
stability tests as well as detailed serum-stability tests should be performed to reduce possible 
protein degradation in vivo. 
Another interesting aspect would be to compare the liCAD format to conventional 
combination therapy, which combines two mAb against an immune checkpoint and a tumor 
target. It would be interesting to see if the liCAD performs similarly or even better than the 
combination of mAbs, since this could decrease therapy costs as well as possible side effects 
due to Fc mediated systemic immune system activation. Moreover, one could transfer the 
idea of locally blocking the CD47-Sirp α interaction by SirpIg to a conventional mAb and 
compare side-by-side the effects of liCADs and these engineered mAbs in order to 
investigate advantages and disadvantages of recruiting specific effector cells via scFvs or any 
Fcγ expressing immune cell. 
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7. ABBREVATIONS 
ADCC Antibody-dependent cellular cytotoxicity 
ADCP Antibody-dependent cellular phagocytosis  
AML Acute myeloid leukemia  
Ang2 Angiopoietin 2 
APC Antigen presenting cell 
ASXL1 Additional sex combs-like 1 
BiTE Bispecific T cell engager 
bsAbs Bispecific antibodies  
CD Cluster of differentiation 
CDC Complement-dependent cytotoxicity 
CDR Complementarity-determining region 
CEA Carcinoembryonic antigen  
CEBPA CCAAT/enhancer-binding protein alpha 
CTLA-4 Cytotoxic T-lymphocyte antigen 4 
DAP12 DNAX activation protein 12  
DC Dendritic cell 
DNA Deoxyribonucleic acid 
DNMT3A DNA methyltransferase 3A 
DVD Dual-Variable-Domain 
EMA European Medicines Agency  
EpCAM Epithelial cell adhesion molecule 
FAK Focal adhesion kinase  
FcγR Fc gamma receptor  
FDA Food and Drug Administration 
FLT3 FMS-related tyrosine kinase 3 
FYB FYN-binding protein 
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GRB2 Growth-factor-receptor-bound protein 2 
GVHD Graft-versus-host disease  
 GVL Graft-versus-leukemia  
HCT Hematopoietic-cell transplantation  
HLA Human leukocyte antigen 
HSCs Hematopoietic stem cells  
IAP Integrin-associated protein  
IDH1 Isocitrate degydrogenase 1 
Ig Immunoglobulin 
IgSF Immunoglobulin superfamily 
IMAC Immobilised metal affinity chromatography  
ImmTACs Immune mobilising monoclonal TCRs Against Cancer 
ITIMs Immunoreceptor tyrosine-based inhibitory motifs  
ITAMs Immunoreceptor tyrosine-based activating motifs  
KD Dissociation constant  
KIR Killer cell immunoglobulin-like receptor 
Lag 3 Lymphocyte activation gene 3  
liCAD Local inhibitory checkpoint antibody derivative 
LSCs Leukemia stem cells  
mAb Monoclonal antibody 
MHC Major histocompatibility complex  
NHL Non-Hodgkin’s lymphoma 
NK cells Natural killer cell 
NPM1 Nucleophosmin family, member 1 
PD-1 Programmed death-1  
PDL1 Programmed death ligand1  
PTPNS1 Protein tyrosine phosphatase, non-receptor type substrate 1 
RBC Red blood cell  
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scFv Single chain fragment variable  
SH2 Src homology 2  
SHP-1 Src homology region 2 domain-containing phosphatase-1 
SHP-2 Src homology region 2 domain-containing phosphatase-2 
Sirp α Signal regulatory protein alpha 
SCAP2 SRC-family-associated phosphoprotein 2  
TCR T cell receptor  
TET2 Tet oncogene family, member 2 
Tim3 T cell membrane protein 3  
TSP-1 Thrombospondin-1 
VEGF Vascular endothelial growth factor 
WT Wilms’ tumor gene 1 
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